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Fast-scan cyclic voltammetry at carbon-fiber microelectrodes (FSCV) is a commonly 
used electrochemical technique to measure sub-second concentration changes in electroactive 
neurotransmitters, including dopamine, and neuromodulators both in vivo and in vitro. FSCV 
provides several advantages, including good chemical selectivity and temporal resolution. Our 
research group is currently interested in studying rapid interactions between neurotransmitters in 
the context of neurodegenerative disease and toxic neurological events. Many research groups 
including ours use rat or mouse animal models to study neurotransmission; however, these 
animal models have some drawbacks, including low throughput analysis and the need to use 
invasive treatment methods, such as intravenous tail injections. In addition, developing 
transgenic rodent models for neurodegenerative disease is expensive and time consuming. 
Therefore, we seek to develop the use of an alternative animal model that has potential for high-
throughput analyses and easy genetic manipulation. 
Zebrafish (Danio rerio) have recently been established as popular animal model for the 
study of neuronal functions due to their fast-life cycle, ease of genetic manipulation and drug 
treatment, and central nervous system similarities with humans. Unfortunately, real time 
measurement methods to study sub-second neurotransmitter release and uptake events in 
zebrafish have not yet been well developed, representing a serious roadblock to the use of this 
organism for elucidating brain function. In this study, FSCV was used to measure locally-evoked 
dopamine release and uptake in zebrafish whole brain preparations as well as brain slices. Our 
results indicate that dopamine release is easily measured in the whole brain. Moreover, peak 
dopamine concentration ([DA]release) was similar to that of sagittal brain slice preparations (0.49 
± 0.13 µM in whole brain and 0.59 ± 0.28 µM  in brain slices, p = 0.41, t-test). Several 
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pharmacological studies using α-methyl-p-tyrosine methyl ester (αMPT), an inhibitor of tyrosine 
hydroxylase, sulpiride, a D2 dopamine autoreceptor antagonist, and nomifensisne, a dopamine 
reuptake inhibitor, were conducted to confirm the presence of dopamine and to determine if 
zebrafish dopamine receptor and transporter are similar to that of rodents.   
In addition to quantifying dopamine release and stimulation optimization, we established 
zebrafish as a chemobrain animal model. We investigated the changes in dopamine release and 
uptake in zebrafish that were treated with chemotherapy drugs, carboplatin and 5-fluorouracil 
using either habitat water treatment or food treatment.  The data here suggest that the 
chemotherapy drugs have an effect on dopamine release and uptake in zebrafish similar to that 
observed in the rodent animal models. Moreover, zebrafish treated orally with chemotherapy 
drugs shown greater effect on evoked dopamine release compared to zebrafish exposed to the 
treated habitat water system.   
Last, our group has been interested in studying the relationship between glutamate and 
dopamine. However, glutamate is neurotoxic and cannot be applied to a harvested brain as was 
the other pharmacological agents. To overcome this challenge, we employed p-
hydroxyphenylacyl (pHP) based caged compounds to deliver glutamate to the target location 
while not interfering with glutamate’s known biological response.  However, direct 
electrochemical quantification of how much glutamate is photo-released is impossible since 
glutamate is not electroactive. Therefore, instead of measuring the amount of glutamate 
photoreleased, we decided to measure 4-hydroxyphenylacetic acid (4HPAA) instead.  4HPAA is 
an electroactive by-product generated from the photostimulation of pHP based caged glutamate. 
Due to the electroactivity of 4HPAA, the amount of photoreleased glutamate can be quantified 
using FSCV.  In addition, our group has successfully demonstrated using both FSCV and high 
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performance liquid chromatograpy (HPLC) that the quantification of 4HPAA indirectly allow for 
the quantification of glutamate generated due to the photoactivation.  Therefore, we studied 
4HPAA’s electrochemistry in order to optimize a waveform for the simultaneous detection of 
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Chapter 1. Introduction 
1.1 Dopamine 
Dopamine is an abundant central nervous system (CNS) neurotransmitter that plays an 
essential role in a wide variety of neurological functions including reward, emotion, locomotion, 
and cognition.  The chemical structure is shown in Fig. 1. In the mammalian brain, shown in Fig. 
2, the dopaminergic system consists of four main pathways; the mesolimbic, nigrostriatal, 
mesocortical, and tuberoinfundibular pathways.   The mesolimbic pathway sends dopaminergic 
projection from the ventral tegmental area of the midbrain to the nucleus accumbens. 1  The 
nigrostriatal pathway sends dopaminergic projection from the substantia nigra to the striatum. 2  
the mesocortical pathway sends dopaminergic projections from ventral tegmental area to the 
cortical structure. 3  Lastly, the tuberoinfundibular pathway sends dopaminergic projection from 










The mesolimbic pathway is predominantly associated with cognitive function, memory, 
and emotion whereas the nigrostriatal is involved with motor function. 7  The mesocortical 
pathway is mainly involved with motivation and reward.8  Lastly, the tuberoinfundibular 
pathway regulates the secretion of prolactin 4.  
 
 
Figure 2. The main four dopaminergic pathways in mammalian brain.  Pathway 1 represents the 
mesolimbolic pathway, pathway 2 represents the mesocortical pathway, pathway 3 represents the 
nigrostiriatal pathway, and pathway 4 represent the tuberoinfundibular pathway.  
 
Dysfunction of the dopaminergic system is known to be related to neurodegenerative 
diseases or neurological disorders. Therefore, understanding the mechanisms and kinetics of 
dopamine neurotransmission is important to gaining an understanding of dopamine’s role in 
these neurological diseases and disorders.  However, the study of dopamine system in the brain 
provides many challenges.  The brain contains a complex environment that can interfere with the 
measurement of dopamine, which is present at low concentration (the basal concentration of 
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dopamine in the caudate-putamen is reported to be around 5 nM). 9 To understand these 
challenges and possible solutions, one must understand how dopamine functions in the brain.  
 
1.1.1 Neurotransmission 
A typical neuron, as shown in Fig. 3, contains a cell body with two types of projections, 
dendrites and axons. Dendrites surround the cell body, receiving signals, whereas axons, 
connected to the cell body, output signals.  In the brain, neurotransmitters act as a small chemical 
messenger to process signals between neurons.  When the neuron receives input signals, various 
ion channels open allowing a rapid influx of Na+ into the neuronal cells. 10 This influx causes a 
depolarization of the cell membrane that leads to a rapid voltage change along the membrane, 
called an action potential. As depolarization continues, the action potential propagates along the 
axon down to the terminals, at the rate of 0.5m/s, resulting in the release of neurotransmitters 












1.1.2 Dopamine release and uptake.  
Once dopamine is synthesized inside the dopaminergic neurons from tyrosine, dopamine 
is packaged into membrane-bound synaptic vesicles by vesicular monoamine transporter 2 
(VMAT2) as shown in Fig. 4.12  Each vesicle contains approximately 0.1 M of dopamine, which 
is 10 – 1000 times higher than dopamine concentration in the cytosol. 13  When the action 
potential reaches the end of axonal terminals, voltage dependent ion channels open causing an 
influx of Ca+2.2, 14  This Ca2+ influx causes the dopamine containing vesicles to fuse to the cell 
membrane within the synapse.  Dopamine stored in the vesicles then releases into the 
extracellular fluid.  This process is called exocytosis, which is related to the external 






Figure 4. The process of dopamine storage, release, and uptake. 
 
 
Once dopamine is released into extracellular fluid by exocytosis, it diffuses across the 
synapse and interacts with dopaminergic receptors located on either postsynaptic or presynaptic 
terminals (Fig. 4).10 16  Most dopamine released is uptaken into the presynaptic terminals by 
dopamine transporter (DAT), a membrane bound protein that regulates the rate of dopamine 
uptake.17 The process of uptake depends on the density of DAT available around the release site, 
and the uptake generally occurs on millisecond time scale.  For example, dopamine is transferred 
back at a maximum rate of 3 µM per second in the rat striatum. 18  After dopamine is transported 
into the presynaptic neurons, dopamine can either be recycled back into the vesicles or 
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metabolized. The concentration of dopamine in the extracellular fluid is controlled by the 
release, uptake and diffusion 19-21.   
 
1.1.3 Dopamine Receptors  
Dopaminergic receptors, G-protein coupled receptors, are divided into two families, D1 
like receptors and D2 like receptors, based on their ability to regulate adenylyl cyclase (AC) 
activity.  These two different families are divided into five subclasses, the D1 like family 
includes D1 and D5 receptors, and D2 like family includes D2, D3, and D4 receptors.  When 
dopamine activates D1 like family receptors, AC activity is stimulated whereas activation of D2 
like family receptors inhibits AC activity14 13.  D1 like family receptors are located 
postsynaptically, and D2 like family receptors are found to be located both postsynaptically and 
presynaptically 2, 8.  
Generally, D2 like family receptors are known to function as autoreceptors, regulating the 
dopamine release mechanism.  When autoreceptors are activated, the inhibition of AC activity 
leads to decreased dopamine release by either reducing neuronal action potential rate or by 
inhibiting dopamine synthesis or release 22-25.   Receptor antagonists and agonists can be used to 
probe the mechanism by which of dopamine release is controlled by these receptors. Receptor 
antagonists bind to the receptors and block the activation site. Receptor agonist also binds to the 
receptor to activate the receptors. For example, D2 receptor agonist, such as quinpirole, can 






1.2 Electrochemical Methods in Neuroscience 
As discussed in previous sections, dopamine release and uptake on millisecond time 
scale; therefore, the dopamine concentration in the extracellular fluid rapidly changes.  
Dopamine is not the only electroactive neurotransmitter available in the brain but also there are 
many others, such as norepinephrine and serotonin.  In addition, there are other electroactive 
species available including ascorbic acid and dopamine metabolites, such as homovanillic acid. 
27, 28   Therefore, to measure and distinguish dopamine release and uptake, the method requires a 
good selectivity, sufficient sensitivity, and sub-second temporal resolution.  
 
1.2.1 Voltammetry 
Voltammetry, the most widely used electrochemical technique for acquiring information 
about electrochemical reactions, was first discovered by a Czech chemist, Jaroslav Heyrovsky, 
who received the Novel Prize in 1959 for inventing polarographic analysis methods. 29 He 
discovered that organic molecules can be reduced at a dropping mercury electrode upon the 
application of a proper voltage 30.  Additionally, he found that the electric current information 
obtained from the electrode is related to the concentration of the reduced molecules.  This current 
information can be plotted as a function of potential to generate a polarogram which can be used 
to identify analytes being reduced both in aqueous and non-aqueous solutions. 30   
Voltammetry, an electrochemical method that measures current as a function of applied 
potential in an electrochemical cell, provides qualitative and quantitative information about 
electroactive species in solutions. 31  There are various voltammetric techniques available based 
on the relationship between the measured current and applied potential, for instance, cyclic 
voltammetry, pulse voltammetry, square wave voltammetry, and so on.  A voltammogram, a plot 
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of current measured as a function of applied potential, is used to determine peak potentials at 
which different electrochemical processes occur.  Therefore, the voltammogram can be used to 
identify the target analyte in solution by observing the shape and the position of the peak 
potential in the plot. 32, 33  
An electrochemical cell consists of either two electrodes or three electrodes system.  Two 
electrodes system, as shown in Fig. 5A, consists of a working electrode and a reference 
electrode. A working electrode provides an electroactive surface where electrochemical reactions 
of the target analytes occur.  The potential applied to the working electrode is measured and 
controlled with respect to a nonpolarizable reference electrode 34. As the current flows in the 
electrochemical cell, potential drop is observed. This potential drop is known as IR drop which is 
governed by Ohm’s Law, E= IR, where I is current and R is the solution resistance 31. The IR 
drop occurs when the differences in the resistance in solution and the potential required to move 
ions in solution is large. The IR drop can affect electrochemical methods by shifting the peak 
potential causing the distortion of voltammetry responses; therefore, the two electrodes system is 
typically used in low resistive solutions. 29, 31     In order to minimize the error caused by IR drop, 
a three electrode system, shown in Fig. 5B, can be used.  The three electrode system consists of a 
counter electrode, in addition to the working electrode and the reference electrode.  The counter 
electrode, generally fabricated using chemically inert metal, such as platinum, provides the 
current required to sustain current flow at the working electrode mitigating the electrochemical 







Figure 5. Schematic diagram of two or three electrode system in electrochemical cell. (A). Two 
electrode system consists of the working electrode (WE) and the reference electrode (RE).  i 
represent an ammeter for measuring the electric current flow. Eapp represents a voltmeter for 
controlling potential applied to WE by measuring potential differences between WE and RE.  (B) 
Three electrode system consists of counter electrode (CE), WE, and RE.   
.  
 
1.2.2 Cyclic Voltammetry  
Cyclic voltammetry is a voltammetric technique that acquires valuable information about 
redox processes, oxidation and reduction reactions, of electroactive species.  Moreover, cyclic 
voltammetry also provides information on electron transfer reactions, chemical reactions, or 
adsorption processes. 35  In cyclic voltammetry, potential is applied linearly to the working 
electrode.  As shown in Fig.6, the potential is applied linearly from initial potential to switching 
potential (forward scan), at which the highest potential is applied.  At the switching potential, the 
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direction of the scan changes back to the initial potential (reverse scan).  The direction of initial 
scan can be either negative, as shown in Fig.6 or positive, depending on the composition of the 
sample.  Typically, one cycle takes less than 100 s and this cycle can be repeated several times. 
34   
As the triangular waveform is applied to the electrode, two different faradaic currents can 
be observed. Anodic current occurs when the analyte in solution is oxidized at the electrode 
surface as the applied potential is reached to more positive potential, causing electrons to flow 
from the analyte to the electrode.  On the other hand, cathodic current occurs when the analyte in 
solution is reduced as the applied potential is scanned to more negative potential, causing 
electrons to flow from the electrode to the analyte in solution. A plot of current responses can be 
generated as the function of applied potentials resulting a cyclic voltammogram. 
Cyclic voltammetry wasn’t applied to measure electroactive molecules in the central 
nervous system in vivo until 1970s. 29 36   Ralph Adams, of the Department of Chemistry at The 
University of Kansas, applied cyclic voltammetry to detect neurotransmitters and their 
metabolites at a miniaturized carbon paste electrode in the rat brains for the first time. 33, 36, 37  
Since then, voltammetry has been used to develop various methods, including constant-potential 
amperometry and fast-scan cyclic voltammetry, which have been employed in various 
applications to understand not only fundamental properties of neurotransmitter release and 






Figure 6. A triangular waveform used in a cyclic voltammetry  
 
 
1.2.3 Fast-Scan Cyclic Voltammetry 
Methodologically, fast-scan cyclic voltammetry is similar to conventional cyclic 
voltammetry in that a triangular waveform is applied to the working electrode.  To perform fast-
scan cyclic voltammetry, the potential is increased linearly to the working electrode from holding 
potential to the switching potential and then scanned back to the holding potential at a fast scan 
rate, typically higher than 100 V/s. 32, 38  This rapid scanning electrochemical method provides a 
cyclic voltammogram, which provides valuable information to identify the target analyte by 
observing the position of oxidation and reduction potential peaks. Moreover, most electroactive 






Figure 7. Fast-scan cyclic voltammetry and dopamine oxidation and reduction reaction.  
 
 
One of challenges of detecting dopamine in the brain is that dopamine is released and 
taken up rapidly on sub-second time scale 14.  The high scan rate used in fast-scan cyclic 
voltammetry offers sub-second temporal resolution 39, 40, which allows the measurement of 
dopamine release and uptake events in the brain.  Moreover, the holding potential, the switching 
potential, and scan rate can be adjusted to improve sensitivity, selectivity, and temporal 
resolution based on the analyte of interest. For example, Fig. 7 shows the commonly employed 
waveform to measure dopamine changes in the brain, in which the potential applied to the 
working electrode is scanned from – 0.4 V to + 1.3 V and back to – 0.4 V at 400 V/s, and this 
cycle is repeated every 100 ms.  As the potential is ramped up linearly, dopamine is oxidized to 
dopamine-o-quinone on the positive sweep and reduced on the negative sweep.  
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One of the major disadvantages of employing the fast scan method is large background 
current generation due to the formation of charging double layers31, 32. This large background 
current exceeds faradaic current, thus making it difficult to observe the current differences. 
However, the large background current is stable between each scan and can be digitally 
subtracted providing background subtracted cyclic voltammogram.   
  
1.2.4 Carbon-Fiber Microelectrodes 
Fast-scan cyclic voltammetry at carbon-fiber microelectrodes, a popular method used to 
understand a sub-second fluctuation of neurotransmissions in the brain, was developed largely by 
the independent work of Martin Fleischmann and R. Mark Wightman around 1980 41.  
Microelectrodes, broadly defined as possessing at least one dimension in micron scale which is 
typically less than 25 μm 42, 43, provide several advantages over other conventional electrodes. 
Due to the small feature of the microelectrodes, the tissue damage occurs during the electrode 
implantation is significantly minimized. 32  Moreover, the diffusional characteristics of 
microelectrodes allow the fast accomplishment of steady-state currents, permitting sub-second 
time regime and minimization of IR drop 44.  Additionally, carbon-fiber microelectrodes may be 
fabricated at low cost and are biologically compatible with the cellular environment.  Typically 
carbon-fiber used to fabricate microelectrodes as range between 5 – 10 µm 45; however, the 
carbon-fiber microelectrodes used in this study, shown in Fig. 8, are fabricated in house using 7 
µm diameter carbon-fiber and cut to 30 – 50 µm in length from the end of pulled capillary. 
 The fabrication process of the carbon-fiber microelectrode is discussed in detail under the 






Figure 8. Scanning electron microscopy image of a carbon-fiber microelectrode 
 
 
1.3 Animal models in neuroscience  
Animal models with simple nervous systems have been widely used in neuroscience 
research to explore monoamine dynamics as well as to gain an understanding of the genetic basis 
of neurological disease. Rodents, especially rats and mice, have been the most commonly used 
animal models in the neuroscience community. 46  Fast-scan cyclic voltammetry at carbon-fiber 
microelectrode have been widely used with rodent models to determine the fast fluctuations of 
neurotransmitter release, including dopamine and serotonin, in both vitro and vivo 47 48-51 
However, rodent model system have several disadvantages.  The life cycle of rats and mice are 
long, increasing the time needed for the identification of neuronal changes in longitudinal studies 
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52. For example, our group used rats for chemobrain model and a month of intravenous injections 
(I.V) of carboplatin administered through the tail vein.53  This I.V tail vein injection is stressful 
both on the rats and person who performs the treatment.  The majority of times, it is hard to 
restrain the rat causing more than one trial to insert syringe needle into the tail vein. 
Additionally, genetic manipulation of rodents, especially rats, is costly and time-consuming 54 55.  
 
1.4 Zebrafish 
Zebrafish (Danio rerio); Fig. 9, has emerged as a popular alternative vertebrate animal 
model to rodents to investigate human disease, extensively used in neuroscience, toxicology, 
pharmacology, and developmental biology. 56-58  Zebrafish were established as an animal model 
in the 1970s by Dr. George Streisinger at the University of Oregon. 57, 59, 60  Zebrafish are small 
and require a simple natural habitat environment; thus it is relatively easier to house zebrafish 
under more natural conditions compared to rodent animal models.  Zebrafish produce a large 
number of eggs, generally 100 – 200, compared to 5 – 10 pups per litter produced by rodents, 
providing the opportunity for high-throughput analyses.61  Zebrafish embryos are transparent and 
develop externally thus permitting researchers to understand how certain genetic gene are 
impacted by either pharmacological treatment or environment changes during the development 
stages, shown in Fig. 10. Zebrafish also share large number of orthologue genes with humans.62 
63 For instance, it appears to be that about 71.4% of human genes contain at least one obvious 
zebrafish orthologue, and 82% of it is related to disease-causing human genes. 63 Additionally, 
the significant contribution to use of zebrafish as animal model is the availability of human 





Figure 9. Image of adult zebrafish.  
 
Genetic manipulations in zebrafish are less costly and more straightforward to perform by 
microinjecting of mRNA encoding the target gene into embryo during the single cell stage64. 
Using such methodology, transgenic zebrafish models for neurodegenerative disorders, such as 
Parkinson’s disease 65, 66, Huntington’s disease 67, and Alzheimer Disease 68, have been 
developed.  Additionally, there are many genetic similarities between the zebrafish and human 
central nervous systems. For instance, zebrafish that model Parkinson’s disease have the parkin 
gene that encodes proteins sharing 62% identity and 92% similarity in its functional domains 69, 




Figure 10. Stages of zebrafish embryonic development. This obtained figure was permitted to 
use from Ref. 64 
 
1.4.1 Zebrafish Dopamine System 
The dopamine system in zebrafish share similarities to that in mammalian systems. Gene 
expression studies have suggested that zebrafish expressed tyrosine hydroxylase (TH) in 
dopaminergic neurons and dopamine transporters 71 and identified D1 and D2 like dopamine 
receptor genes 72. Immunohistochemistry studies in zebrafish have shown that the dopaminergic 
neurons can be differentiated as early as 18 hours post fertilization (hpf) and their dopamine 
system is well advanced by 72 hpf 71.  Moreover, the most of dopamine neuronal cluster was 
found to be located in diencephalon and no dopamine cluster was observed in the hindbrain.  
The ventral telencephalon, shown in Fig. 11, the target region of the brain we are 
interested to measure dopamine release and uptake, is suggested to be analogous to that of 
striatum in human. 73, 74  In addition, zebrafish dopaminergic neurons send ascending projection 
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from ventral diencephalon, known to contain the majority population of dopamine cluster, to the 
ventral telencephalon 75. This ascending dopaminergic pathway, shown in Fig. 12, is suggested 
to be similar to nigrostriatal pathways in mammalian dopamine system 75.   
 
 





Figure 12. Schematic sagittal view of comparing dopaminergic neuronal population in zebrafish 
in green dots (A) and schematic view of the location of dopaminergic projection in adult 













1.4.2 Measurement of Dopamine in Zebrafish 
Immunohistochemistry with high resolution imaging technique have been successfully used 
in zebrafish to understand the anatomy of neurotransmitters system in the brain. 76-78  These 
methods have been helpful in understanding how neurotransmitters are distributed in developing 
in zebrafish; however, these methods do not inform how zebrafish neurotransmitter function 
differs from that of rodents.  
High pressure liquid chromatography (HPLC) has been employed to quantify the amount 
dopamine and their metabolites in zebrafish and determine changes in dopamine content. 
Chartterjee et al. applied HPLC, for the first time, to analyze alcohol induced dopamine changes 
in zebrafish 79  Moreover, HPLC was coupled with mass spectrometry to identify and quantify 
more than 17 neurotransmitters throughout the zebrafish life cycle. 80  Electrophysiology is 
another technique used in zebrafish to improve understanding of the central nervous system. 81 
However, elucidating the neurotransmission in zebrafish compared to that of rodents is critical to 
extend the use of zebrafish as useful model in neuroscience. Therefore, direct measurement of 
neurotransmitter release and uptake is necessary.   
The real-time measurement of dopamine in zebrafish has not been extensively 
investigated.  Recently, Jones, et al. measured dopamine release in sagittal slices of zebrafish 
brain with fast-scan cyclic voltammetry at carbon-fiber microelectrodes.82  In this study, they 
measured neurotransmitter release upon the application of either electrical stimulation or high 
concentration of K+ at telencephalon using a saw tooth waveform. This study represent that the 
direct measurement of neurotransmitter release can be done in zebrafish brain using the 
electrochemical method. Neurotransmitter release study in brain slices haven been extensively 
done in rodents yielding much more information related to not only dopamine regulations in 
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different disease states but also the characterization of dopamine release and uptake kinetics. 
However, brain slice experiments can provide some drawback, such as disrupting the neuronal 
pathways 83 and causing tissue damage due to slice preparation.  
Another study recently done to monitor real time measurement of dopamine release was 
conducted in larval zebrafish. In this study, Shang et al. developed a real- time method using 
amperometric detection method with carbon-fiber microelectrode to observe differences in 
response after introducing food extract to one of nostrils.84  Moreover, in vivo imaging method 
was employed to understand the circuitry mechanism of dopamine release demonstrating that 
pretectal dopaminergic neurons are involved in evoked dopamine release in olfactory. This study 
was innovative since the experiment was done in vivo using larva zebrafish; however, it is 
practically difficult to measure dopamine release in adult zebrafish; limiting to study dopamine 
release throughout the life cycle.  
 
 
1.5 The Summary of the Following Chapters 
The goal of this introduction chapter was to provide background information about the 
detection methodology, dopamine, and animal models used in neuroscience research. The 
following chapters will be focused on developing methods to measure sub-second dopamine 
release in ex-vivo, harvested whole brain, and brain slices, with FSCV. 
The Chapter 2 is focused on developing a robust protocol to position both stimulation and 
working electrodes in the whole brain to measure dopamine release and provide evidence of 
dopamine release upon the electrical stimulation by conducting several pharmacological studies. 
Dopamine release was measured not only in the harvested whole brain and but also different 
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brain slice preparations, coronal and sagittal slices. Moreover, the amount of dopamine was 
calculated using calibration factors obtained from measuring current responses against known 
concentrations and comparing different brain preparations and before and after pharmacological 
manipulation. 
Chapter 3 is focused on developing zebrafish as a possible chemobrain model by treating 
zebrafish with carboplatin and 5-fluorouracil. In addition, drug was administrated to zebrafish by 
two different pathways: the habitat water treatment and food treatment. Once zebrafish were 
treated with each drug by different pathways, electrically evoked dopamine release was 
measured and compared.  
Finally, Chapter 4 discusses about developing a method to quantitatively and 
simultaneously measure dopamine and 4-hydroxyphenylacetic acid (4HPAA).  In addition, the 
oxidation mechanism of 4HPAA was studied and the waveform was optimized to enhance the 
sensitivity, selectivity, and temporal resolution of 4HPAA and dopamine detection. The reason 
we studied 4HPAA was because 4HPAA is the by-product of p-hydroxyphenylglutamage (pHP-
Glu), caged glutamate used to improve spatial resolution of drug delivery to the targeted area 
thorough the simple process of photostimulation. Therefore, by determining the amount of 
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Chapter 2. Measurement of dopamine release and uptake in zebrafish 
Development of a robust protocol to electrically evoke and measure dopamine release and 
uptake using fast-scan cyclic voltammetry at carbon-fiber microelectrodes in harvested zebrafish 
whole brain and brain slices is discussed in this chapter.   The results presented in this chapter are 
from “Ex vivo Measurement of Electrically Evoked Dopamine Release in Zebrafish Whole Brain” 
that has been submitted to ACS Chemical Neuroscience. 
 
2.1 Introduction 
Zebrafish (Danio rerio) are teleosts that were initially established as a model organism in 
the 1970s by George Streisinger for the study of development 1-3.  Recently, zebrafish have 
emerged as a desirable model for the study of neuronal function 4, 5  because they approximate the 
human central nervous system more accurately than invertebrates and are easier to genetically 
manipulate than rodents 6.  Moreover, the optical transparency of zebrafish larvae make this 
organism well-suited for in vivo studies in which intracellular calcium changes 7, 8 and action 
potentials 9can be imaged in real-time.  Also, the zebrafish central nervous system, when studied 
using cultured cells 10, brain slices 11, and intact brain 12, 13, has proven amenable to 
electrophysiological measurements of neuronal firing. 
In addition to these methods, the use of electrochemistry to measure the release and uptake 
of neurotransmitters in zebrafish is just now being realized.  Fast-scan cyclic voltammetry (FSCV) 
at carbon-fiber electrodes is an electrochemical technique that provides good chemical selectivity 
and sub-second temporal resolution, allowing the measurement of release and uptake of 
electroactive neurotransmitters 14-17.  FSCV has been used extensively in rodents to measure the 
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release and uptake dynamics of dopamine, an abundant catecholamine neurotransmitter that plays 
a role in many aspects of neurological function, including the control of intentional movement  18, 
19, cognition 20, and reward 21, 22. 
Recently, the release of dopamine and other neurotransmitters was measured in brain slices 
acutely harvested from zebrafish 23.  The analysis of brain slices from various neuronal systems, 
including rodents, has yielded much information regarding disease state mechanisms 24-28 and 
fundamental neurotransmitter release properties 29.  However, brain slice preparations have several 
drawbacks such as cellular damage induced at the surface of the slice 30-32 and difficulty in 
capturing entire neuronal pathways 33, 34.  
The use of intact brains could mitigate these problems by decreasing the amount of tissue 
damage and leaving the neuronal pathways intact, thereby allowing remote stimulation of the 
pathway and eliminating the release of interfering neurotransmitters and neuromodulators that 
would be present upon local stimulation.  However, electrochemical neurotransmitter release 
measurements within the intact brain of zebrafish have not yet been reported in the literature; thus, 
the measurement of locally-stimulated dopamine release from acutely harvested, intact zebrafish 
brains, and comparison of these measurements with those from brain slices, represents a critical 
first step. 
Here, we describe measurements of dopamine release and uptake in whole, intact zebrafish 
brains with FSCV.  Furthermore, we compare these measurements to those obtained in sagittal and 
coronal brain slices.  We found that, when the working electrode is properly placed by reference 
to the external features of the removed brain, electrically evoked dopamine release and uptake is 
easily measured in zebrafish whole brain ex vivo.  The cyclic voltammograms obtained strongly 
suggest that the neurotransmitter measured is dopamine.  Moreover, we confirmed the detection 
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of dopamine with pharmacological agents that alter dopamine release and uptake.  These results 
support the use of FSCV in ex vivo whole brain preparations as a useful analytical tool for 
measuring neurotransmitter release and uptake in zebrafish. 
 
2.2 Summary of the Studies Described in This Chapter 
This chapter demonstrates the electrochemical measurements of dopamine release and 
uptake in different zebrafish brain preparations, such as whole brains, sagittal slices, and coronal 
slices. In these studies, we develop a robust procedure to accurately position stimulating and 
working electrodes in order to measure evoked dopamine and conduct pharmacological studies, 
especially in harvested whole brains. The experiments were performed using wild type adult 
zebrafish. 
 
2.3. Materials and Methods 
2.3.1 Zebrafish 
All animal procedures were approved by the University of Kansas Institutional Animal 
Care and Use Committee.   Adult zebrafish used for these studies were housed in the Molecular 
Probes Core of the Center for Molecular Analysis of Disease Pathways at the University of Kansas.  
Zebrafish were euthanized by rapid chilling, also known as hypothermic shock.  To perform 
euthanasia, the main system water was chilled to 2-4 ̊C.  Zebrafish then were transferred by a net 
from an Aquatic Habitats™ ZF0601 (Pentair, Cary, NC, USA), the main housing system, into the 






2.3.1.1 Zebrafish Whole Brain Preparation 
The whole brain preparation method was modified from the procedure described 
previously 35.  To harvest a whole brain from a zebrafish, a euthanized zebrafish was decapitated 
using a 0.009” single edge blades (VWR Corporates, Radnor, PA, USA).  As shown in figure 1A, 
the decapitated zebrafish head was inserted into pre-prepared dissection pads made with 2% 
agarose (BioReagent graded agarose, Sigma-Aldrich, St. Louis, MO, USA)  in 100mm x 15mm 
petri dishes (ThermoFisher Scientific, Waltham, MA, USA).  The petri dish was filled with 
oxygenated (95% O2 / 5% CO2) zebrafish ice-cold artificial cerebral spinal fluid (ZF aCSF).   
The ZF aCSF consisted of 131 mM NaCl, 2 mM KCl, 1.25 mM KH2PO4, 20 mM NaHCO3, 
2 mM MgSO4, 10 mM glucose, 2.5 mM CaCl2·H2O, and 10 mM HEPES, and the pH was adjusted 
to 7.4.  The decapitated zebrafish head was then fixed by pinning it with a syringe needle.  The 
skull of the zebrafish was carefully removed using micro tweezers and forceps, and the brain was 
accurately removed with a pulled capillary.  The brain was then transferred into the recording 
chamber that was perfused with oxygenated ZF aCSF and the brain was kept at physiological 
temperature of 28 ̊C.  The brain was placed ventral side face up to expose the sub pallium in 
telencephalon, the region of interest containing dopaminergic innervation 36. Then the brain was 
immobilized by placement of a nylon mesh harp on the top. Prior to measurements, the brain was 




Figure 1. Adult zebrafish whole brain preparation. A. Image of decapitated zebrafish head pinned 
with a syringe needle in 2% agarose covered petri dish. The petri dish was filled with oxygenated 
ZF aCSF. B. Image of zebrafish head exposed its brain after the skull was removed using micro-
tweezer. C. Image of FSCV recording setup. The harvested zebrafish brain was placed in the 
recording chamber that was perfused with oxygenated ZF aCSF and the brain was held in the 
chamber placing a nylon mesh harp on top. 
 
2.3.1.2 Zebrafish Brain Slice Preparation. 
Harvested brains were suspended in 2% low gelling point agarose (Agarose type VII-A, 
Sigma-Aldrich, St Louis, MO, USA) prepared in 50 % distilled water and 50% oxygenated ZF 
aCSF.  After the agarose hardened, a block of agarose containing the brain was cut off and glued 
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onto a specimen disk and fastened in the buffer tray of a vibratome (Leica microsystem, 
Bannockburn, IL, USA).  The tray was then filled with ice cold oxygenated ZF aCSF and kept at 
2 – 4 ̊C during the slicing process.  Sagittal and coronal slices, 350 µm thick, were prepared and 
transferred to the recording chamber.  Prior to the experiments, brain slices were allowed to 
equilibrate for 1 hour. 
 
2.3.2 Carbon Fiber Microelectrodes Fabrication. 
Cylindrical carbon fiber microelectrodes were fabricated as previously described 37. 
Briefly, 7 µm diameter carbon fiber (Goodfellow Cambridge LTD, Huntingdon, UK) were 
aspirated into a glass capillary tubes (1.2 mm D.D and 0.68 mm I.D, 4 in long; A-M System Inc, 
Carlsborg, WA, USA).  Loaded capillaries were then pulled using a PE-22 heated coil puller 
(Narishige Int. USA, East Meadow, NY, USA).  Pulled carbon fibers were trimmed to a length of 
30 µm from the pulled glass tip. To seal the carbon fiber, electrodes were dipped into epoxy resin 
(EPON resin 815C and EPIKURE 3234 curing agent, miller-Stephenson, Danbury, CT, USA) and 
cured at 100 ̊C for 1 hour.  Prior to the experiments, the electrodes were soaked in isopropanol for 
10 minutes, and the electrode surface was electrochemically pretreated by scanning the electrodes 
with the waveform of – 0.4 V to + 1.3 V back to – 0.4 V at a frequency of 60 Hz for 15 min 
followed by 10 Hz for 10 min.  Electrodes were then backfilled with 0.5 M potassium acetate for 







2.3.3 Electrochemical Measurements 
2.3.3.1 Data Acquisition and Statistics 
Electrochemical measurements were collected and analyzed using an electrochemical 
workstation consisting of a Dagan Chem-Clamp potentiostat (Dagan, Minneapolis, MN, USA), 
modified to allow gain settings down to 200 nA/V, a personal computer with TarHeel CV software 
(provided by R.M. Wightman, University of North Carolina, Chapel Hill, NC, USA), a UEI 
breakout box (UNC Chemistry Department Electronics Design Facility, Chapel Hills, NC, USA), 
and two National Instruments computer interface cards, PCI 6052 and PCI 6711 (National 
Instruments, Austin, TX, USA). 
All numerical values were represented as mean ± standard error of the mean (SEM). For 
all analysis, n is equal to the number of zebrafish brains used.  GraphPad Prism 6 (GraphPad 
Software Inc, La Jolla, CA, USA) was used to conduct statistical calculations and to present data. 
 
2.3.3.2 Dopamine Measurements in Zebrafish Whole Brain and Brain Slices 
Carbon-fiber microelectrodes were pre-calibrated against 3 µM dopamine, and the 
electrode surface was chemically and electrochemically purified as discussed under the electrode 
fabrication method.  The pre-calibrated carbon-fiber microelectrode and the stimulating electrodes 
(A-M System Inc, Carlsberg, WA, USA) were micromanipulated into the place by referencing the 
external features of the ventral side of the brain.  The carbon-fiber microelectrode was positioned 
50 – 100 µm laterally from the medial olfactory tract (MOT) and inserted about 280 – 300 µm 
deep.   Stimulating electrodes were placed at the center of ventral telencephalon and inserted about 




To evoke dopamine release, 25 electrical pulses (350 µA stimulating current, 4 ms of total 
duration, and stimulating frequency of 60 Hz) were applied.  After the stimulating current was 
applied, evoked dopamine release was measured at the surface of the carbon-fiber microelectrodes.  
For dopamine detection, a triangular waveform of – 0.4 V to + 1.3 V to – 0.4 V at a scan rate of 
400 V/s was applied to the carbon-fiber microelectrode every 100 ms.  After stimulation and 
dopamine detection, the brain underwent 10 minutes of resting time before the next stimulation 
was applied. 
In experiments, where evoked dopamine release in sagittal or coronal slices was measured, 
the same stimulating and waveform parameters were used as the harvested whole brain 
experiment. Stimulating electrodes were positioned at the ventral side of brain slices and inserted 
about 100 µm into the brain slice.  The carbon-fiber microelectrode was inserted about 150 µm 
and placed between stimulating electrodes.  Moreover, the brain slices were allowed to rest for 10 
minutes between measurements. 
  
2.3.4 Materials 
Dopamine, α-methyl-p-tyrosine methyl ester (αMPT), nomifensine, and (±) sulpride, were 
purchased from Sigma-Aldrich (St. Louis, MO,USA). All aqueous solutions were made with 
purified (18.2 MΩ) water.  A modified artificial cerebrospinal fluid (aCSF) for zebrafish consisted 
of 131 mM NaCl, 2mM KCl, 1.25 mM KH2PO4, 20 mM NaHCO3, 2mM MgSO4, 10 mM glucose, 
2.5 mM CaCl2·H2O, and 10mM HEPES, and the pH was adjusted to 7.4. Dopamine stock solutions 
were prepared in 0.2 M perchloric acid and were diluted with aCSF without glucose to 3 µM for 
pre/post calibrations.  Solutions of 50 µM aMPT, 10 µM of nomifensine, and sulpride, were 




2.4 Results and Discussion 
Zebrafish (Danio rerio) have recently emerged as useful model organism for the study of 
neuronal functions.  Fast-scan cyclic voltammetry at carbon-fiber microelectrodes (FSCV) has 
been used for the real time measurements of release and uptake of neurotransmitters both in vivo 
and vitro in different animal models, such as rodents and fruit flies 38, 39.  However, real time 
measurements of dopamine release in zebrafish using FSCV has not been studied extensively.  
Here, for the first time, we measure locally-evoked dopamine release and uptake in zebrafish whole 
brain preparations, and results were compared with those obtained from brain slices.  The peak 
dopamine concentration ([DA] release) was similar in both whole brain and brain slice preparations. 
Treatment with α-methyl-p-tyrosine methyl ester (αMPT), an inhibitor of tyrosine 
hydroxylase, diminished release, and the electrochemical signal reappeared after subsequent 
washout, confirming the presence of dopamine.  Uptake was inhibited in whole brain and slices 
following treatment with nomifensine.  Furthermore, treatment the zebrafish brain with sulpiride, 
a D2 dopamine autoreceptor antagonist, resulted in increased stimulated dopamine release in 
whole brain and the results were compared with sagittal and coronal slices. 
 
 
2.4.1 Evoked Dopamine Releases in Harvested Whole Brain. 
We measured the electrically evoked dopamine release and uptake in harvested whole brain 
preparations from zebrafish (Fig. 2).  A photograph of a viable whole brain acutely harvested from 
an adult zebrafish is shown in Fig. 2A.  The brain is situated ventral side up to provide easier access 
to the subpallium in the telencephalon, a region of the brain that contains dopaminergic innervation 
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35-37.  The carbon-fiber microelectrode and the stimulation electrodes were micromanipulated into 
place by referencing the external features of the ventral side of the brain.  The carbon-fiber 
microelectrode was positioned 50-100 µm laterally from the medial olfactory tract (MOT) and 
inserted 280–300 µm deep.  The region was stimulated locally with a biphasic stimulus pulse 
regimen of 25 pulses, 2 ms duration and 350 µA current.  Application of this regimen resulted in 
the release of dopamine detected by FSCV at the carbon-fiber microelectrode (Fig. 2B).  A 
stimulated release plot, current versus time profile, sampled from the color plot at the horizontal 
dotted line, is located above the color plot. A CV, sampled at the vertical dashed line of the color 

















Figure 2. Electrically evoked dopamine release from a harvested whole brain.  (A) Image of a 
harvested zebrafish whole brain indicating the placement of carbon-fiber microelectrode and 
stimulating electrodes in the ventral telencephalon.  (B) Representative data of evoked dopamine 
release in whole brain. Stimulated dopamine release plot (top), current versus time, was sampled 
at the horizontal white dashed lines of color plot (bottom). A background subtracted cyclic 
voltammogram (insert, top) was sampled at the vertical white dashed lines of the color plot. 
 
2.4.2 Evoked Dopamine Release in Brain Slices. 
For comparison, dopamine release was also measured in acutely harvested sagittal brain 
slices (Fig. 3) and coronal slices (Fig. 4). The stimulation and working electrodes were 
micromanipulated into position at the ventral telencephalon.  Dopamine release was evoked locally 
using the same stimulation parameters used in the whole brain.  Both CV and current versus time 
plots are similar to those obtained in the whole brain preparation.  In the representative raw data, 
[DA] release increased until a peak concentration of about 1 µM was measured ~2 s after stimulus 
application.  [DA] release then decreased as uptake occurred.  The color plots suggest that other 
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electroactive species were not released in substantial quantities.  Also, [DA] release throughout the 
experiment was stable in both preparations.  
 
 
Figure 3. Electrically evoked dopamine release from a sagittal slice. (A) Image of a sagittal slice 
indicating the placement of carbon-fiber microelectrode and stimulating electrodes in the ventral 
telencephalon. (B) Representative data of evoked dopamine release in a sagittal slice. Stimulated 
dopamine release plot (top), current versus time, was sampled at the horizontal white dashed lines 
of color plot (bottom). A background subtracted cyclic voltammogram (insert, top) was sampled 
at the vertical white dashed lines of the color plot. 
 
 
Dopamine release measurements in both preparations were collected for one hour and 
compared.  Data pooled from multiple whole brains and brain slices reveal that, under equivalent 
stimulation conditions, average [DA] release was not significantly different in whole brain and slices: 
0.41 ± 0.07 µM in whole brains, 0.54 ± 0.13 µM in sagittal slices, and 0.44 ± 0.09 µM coronal 
slices (p = 0.40, n=9 sagittal slices, n= 9 coronal slices and 9 brains, t-test).  The concentration of 
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dopamine release evoked by either single or multiple stimulus pulses, both in vivo and in vitro, has 
been reported extensively in the literature.  For example, application of a single pulse in mouse 
brain slices resulted in 1.43 ± 0.11 µM (striatum) 40 , 1.42 ± 0.14 µM (nucleus accumbens core), 
and 1.40 ± 0.19 µM (caudate putamen) 41.  Multiple stimulation pulses were applied in vivo to 
evoke dopamine release in the rat striatum at a reported peak concentration of 1.04 ± 0.14 µM 42.  
Recently, Jones et al. 23 found dopamine to be released in zebrafish sagittal slices at a peak 
concentration of about 100 nM following stimulation with 20, 4-ms duration pulses applied at a 
current of 500 µA and an application frequency of 60 Hz. In any case, it appears from our results 












Figure 4. Electrically evoked dopamine release from a coronal slice.  (A) Image of a coronal slice 
indicating the placement of carbon-fiber microelectrode and stimulating electrodes in the ventral 
telencephalon.  (B) Representative data of evoked dopamine release in a coronal slice. Stimulated 
dopamine release plot (top), current versus time, was sampled at the horizontal white dashed lines 
of color plot (bottom).  A background subtracted cyclic voltammogram (insert, top) was sampled 
at the vertical white dashed lines of the color plot. 
 
2.4.3. Effect of DAT inhibitors on evoked dopamine release. 
Extracellular dopamine levels are tightly regulated by the dopamine transporter (DAT), a 
membrane-bound protein that transfers dopamine molecules from the extracellular space to the 
intracellular space within neurons 43.  The stimulated release plot reveals that, similar to the 
mammalian brain, dopamine is immediately taken up after release.  Based on previous 
measurements in brain slices from mice that lack the DAT 44, 45, it is likely that dopamine is actively 
taken up and that the decrease in current is not the result of diffusion away from the electrode. 
Additional pharmacological studies were conducted in which whole brain and sagittal and 
coronal slices were perfused with nomifensine (Fig. 5), a well-established dopamine uptake 
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inhibitor 43.  As a result, the rate of dopamine uptake was sharply diminished, indicated by the 
decreased slope of the stimulated release curves after peak dopamine release.  This treatment 
resulted in a ~130% increase in [DA] release in the whole brain preparation (Fig. 5A: pre-drug, 0.34 
± 0.14 µM; post-drug, 0.79 ± 0.22 µM, p < 0.05, n = 4 brains, t-test).  A similar effect was observed 
when treating sagittal slices with nomifensine, with [DA] release increasing ~100% (Fig. 5B: pre-
drug, 0.49 ± 0.13 µM; post-drug, 0.97 ± 0.18 µM, p < 0.05, n = 5 slices, t-test). Moreover, evoked 
dopamine release in coronal slices was altered by ~100% after nomifensine was introduced (Fig. 
5C: pre-drug, 0.42 ± 0.11 µM; post-drug, 0.82 ± 0.13 µM, p < 0.05, n = 4 slices, t-test).   Jones et 
al. demonstrated the release of dopamine in the ventral telencephalon of zebrafish sagittal slices 
23.  Collectively, our result suggests that extracellular dopamine levels are tightly regulated in the 
telencephalon immediately after release.  However, ex vivo whole brain preparations can be used 





Figure 5. The effect of DAT inhibition on dopamine release in whole brain and sagittal and coronal 
brain slices. Dopamine release was measured before and after 10 µM nomifensine was 
administered to whole brains (A) and sagittal (B) and coronal brain slices (C). Color plots (bottom) 
and current versus time profiles (top) before and after application of nomifensine show that 
dopamine uptake was diminished in each brain preparation. (D) Evoked dopamine release in whole 
brain after nomifensine addition was significantly increased (n=4, P < 0.05, t-test). Similar to the 
whole brain results, dopamine release in brain slices significantly increased upon treatment with 






2.4.4. Effect of dopamine synthesis inhibitor on evoked dopamine release. 
In order to obtain further confirmation that the neurotransmitter being measured is 
dopamine, we examined the effect of α-methyl-p-tyrosine methyl ester (αMPT), which inhibits 
tyrosine hydroxylase and blocks dopamine synthesis, on release (Fig. 6A).  Dopamine was 
electrically-evoked and measured every 10 minutes.  Upon stabilization of the dopamine signal, 
brains were perfused with 50 µM αMPT and, approximately 2 hours later, dopamine release 
completely disappeared (pre-drug, 0.56 ± 0.08 µM; post-drug, 0.14 ± 0.07 µM, p < 0.0001, one-
way ANOVA).   To ensure that this disappearance of release was not due simply to loss of neuronal 
viability, the drug was washed out, and release re-appeared approximately 1 hour later (washout, 
0.51 ± 0.10 µM, p = 0.40, one-way ANOVA), indicating that dopamine release was not 
significantly different than before the drug was added and providing further confirmation that the 




Figure 6. The effect of dopamine synthesis inhibition on dopamine signal.  (A) Representative 
data of stimulated dopamine release before (left) and after (center) administration of 50 µM αMPT.  
Dopamine release reappeared after a 1-hour washout with drug-free buffer solution in the same 
recording session (right).  Cyclic voltammograms for each step (inserts) confirm the release of 
dopamine.  (B) Evoked dopamine release, measured after 2 hours of treatment with αMPT, 
significantly decreased (n=5, P < 0.0001, one-way AVOVA).   Dopamine release after washout 







2.4.5. Effect of dopamine receptor antagonist on evoked dopamine release. 
Dopaminergic terminals in the mammalian striatum possess D2-family dopamine 
autoreceptors that serve as a regulatory feedback mechanism for dopamine release 43.  To 
determine if a similar self-regulatory mechanism is present in dopaminergic terminals of the 
subpallium, we perfused whole brain ex vivo preparations with 10 µM sulpiride, a D2-family 
dopamine receptor inhibitor (Fig. 7A). Approximately 1 hour after addition of drug, dopamine 
release increased by about 80% (pre-drug, 0.41 ± 0.12 µM; post-drug, 0.74 ± 0.13 µM, p < 0.05, 
two-way ANOVA).   Thus, D2 receptors are also present in the zebrafish brain and appear to serve 
a similar regulatory function.  However, given that the circuitry is still intact in the whole brain 
preparation, it is also possible that sulpiride may enhance the release of dopamine by antagonism 
of dopamine receptors located not only presynaptically, but also at other locations within the brain 
46. 
To determine if autoregulation by D2 receptors occurs specifically at terminals, 
electrically-evoked dopamine release was measured in the subpallium of sagittal brain slices 
before and after sulpiride treatment (Fig. 7B).  The slicing process should at least partially disrupt 
the ascending dopaminergic pathway from the diencephalon to the subpallium, likely leaving only 
presynaptic terminals without dopaminergic soma 36, 47.   In this case, [DA]release in the sagittal slice 
preparation increased by about 100% on average within an hour of treatment with 10 µM sulpiride  
(pre-drug, 0.33 ± 0.12 µM; post-drug, 0.68 ± 0.29 µM, p < 0.05, n = 5 slices, two-way ANOVA).  
However, it is possible that, given the thickness of the slices (350 µm), a substantial portion of the 
pathway remained.  Interestingly, when the brain was sliced coronally, D2 antagonism with 




Figure 7. Effect of sulpiride treatment on dopamine release. Evoked dopamine release measured 
in a whole brain (A), a coronal slice (B), and a sagittal slice (C) before and after treatment with 10 
µM sulpiride. (D) Dopamine release significantly increased in whole brains (n=5, p < 0.05, two-
way ANOVA) and sagittal slices (n=5, p < 0.05, two-way ANOVA) after drug treatment. 
However, dopamine release did not significantly increase in coronal slices after drug treatment (n= 
5, p = 0.99, two-way ANOVA). 
 
 
Our results here show that dopamine release did not increase upon exposure to sulpiride 
(pre-drug, 0.35 ± 0.12 µM; post-drug, 0.38 ± 0.10 µM, p = 0.47, n = 5 slices, two-way ANOVA), 
suggesting that the D2-related mechanism of auto-inhibition in slices is not present in the coronal 
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preparation.  The reason for this lack of effect is not well-understood.  However, it is possible that 
the D2 receptors are not located presynaptically, but rather on the soma. 44 Another possibility is 
that the coronal slicing process induces more damage to the terminals compared to slicing 
sagittally.  Additional studies will be required to identify the underlying mechanisms of this 
phenomenon. 
 
2.4.6 Effect of stimulation frequency on evoked dopamine release. 
The degree of dopamine release is determined, in part, by the number of stimulus pulses 
and the frequency (number of biphasic pulses applied per second).45 Initially, to determine if 
alteration of stimulation frequency impacts dopamine release similarly in zebrafish, evoked 
dopamine both in whole brain and sagittal slices was measured and compared at frequencies 
ranging from 5 Hz to 25 Hz while other stimulus parameters were held constant (120 pulses, 4 ms, 





Figure 8. Effect of stimulation frequency on dopamine release. The stimulation frequency was 
altered while stimulation pulses and width were kept constant (120 pulses, 4 ms pulse duration) 
and evoked dopamine release was measured both in whole brain and sagittal slices. Linear 
regression analysis lines are shown for both whole brain (dashed line) and brain slice (dotted line). 
 
We found a trend of increasing dopamine release up to a frequency of 25 Hz in whole 
brains. Although there appears to be a slight curvature, linear regression analysis revealed a strong 
correlation coefficient of linearity (R2=0.96) and also a significantly non-zero slope (p = 0.0030). 
However, in slices, dopamine release wasn’t influenced much by stimulation frequency compared 
to that in whole brains. The difference in dopamine release may suggest that the preparation 
impacts the availability of vesicles for release.  Indeed, progressively decreasing in dopamine 
release 28 were observed in rodent brain slices and linear increases were observed in vivo 37 when 
stimulation frequency was increased.  While the causes underlying these differences are not 
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known, it is possible that higher stimulation frequencies result in mobilization of reserve pool 
vesicles, as our previous results in striatal mouse brain slices have suggested 28.  In fact, this 
decrease in release at higher frequencies was exaggerated in transgenic R6/2 mice, which are 
commonly used to model Huntington’s disease (HD).  Our previous results have suggested that 
this decrease is likely due to a diminished reserve pool in R6/2 mice. In the future, it will be 
interesting to determine if these differences between slices and whole brain arise from a diminished 
reserve pool or have some other cause. 
 
2.5 Conclusion 
In conclusion, we have shown that dopamine release can be easily measured with FSCV in 
the subpallium of zebrafish whole brain.  This preparation offers the advantage of keeping the 
whole brain intact, thereby preserving the three-dimensional neuronal circuitry and offering the 
future possibility of measuring release evoked by stimulation of pathways.  Similar to slices, 
extracellular dopamine levels are tightly regulated by uptake through the DAT.  Our results also 
demonstrate that uptake is inhibited by nomifensine in both brain slice and whole brain 
preparations.  Additionally, D2 autoreceptors appear to regulate dopamine release in whole brain 
and sagittal slice preparations, but not in coronal slice preparations.  Moreover, dopamine release 
properties from the whole brain are similar to those from brain slice preparations under similar 
conditions of electrical stimulation.  These results represent an important step toward more 
complex studies, such as FSCV experiments that make use of remote stimulation in zebrafish 
whole brain and measurements of dopamine release in vivo.  Furthermore, the expanded use of 
this model organism will allow researchers to exploit the genetic advantages of zebrafish in the 
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Chapter 3. Effect of Chemotherapeutic Drugs on Evoked Dopamine Release  
in Zebrafish 
Using zebrafish as a possible chemobrain animal model is discussed in this chapter. To 
determine whether chemotherapeutic agents have a similar effect on zebrafish as has been 
observed in rats, zebrafish were treated with carboplatin and 5-fluorouracil by different drug 
administration pathways, habitat water treatment or food treatment. The data used in this chapter 
is from “Electrochemical Measurement of Evoked Dopamine Release in Zebrafish Treated with 
Chemotherapy Drugs”, which is in preparation.  
 
3.1 Introduction 
Advances in cancer detection and treatment have extended the lifespan of cancer survivors, 
especially those who have undergone chemotherapy treatment for breast cancer.1 This increased 
lifespan brought to light the quality of patients’ lives after chemotherapy treatment has concluded. 
Post-chemotherapy cognitive impairment, also known as chemobrain, is a syndrome characterized 
by deficits in memory and executive function that occur well after conclusion of treatment 2. 
Unfortunately, the actual causes of chemobrain are still uncertain, although several mechanisms 
have been suggested.  These include chemotherapy-induced DNA damage, disruption of vascular 
blood flow in the brain, and impairment of neurotransmitter signals due to the chronic toxicity of 
chemotherapy drugs 3-5.  
Dopamine is a monoamine neurotransmitter in the central nervous system that is involved 
in many neurological functions, including cognition6, reward7, and locomotor control. 6, 8  In 
addition, dysfunction of the dopamine system has been shown to be associated with a various 
clinical problems such as Parkinson’s disease 9, Huntington’s disease 10-12, and Alzheimer disease 
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13.  Our group recently observed that electrically evoked dopamine release and uptake was altered 
in the striatum of rats treated with carboplatin, a chemotherapeutic agent often used to treat cancers 
of the head, neck, breast, and lung 14.  Despite the decrease in release, reserve pool dopamine 
storage and total dopamine content in the brain tissue were unaffected, suggesting that sufficient 
neurotransmitter levels were available in the neurons, but they could not be effectively released. 
Importantly, this diminished release also corresponded to an impairment of spatial learning.   
Rats and mice have commonly been used as models to understand fundamental 
mechanisms underlying the onset of neurodegenerative disease states, such as Huntington’s 
disease 15 and Parkinson’s disease 9, 16.  However, although they are genetically closer to humans 
than non-mammalian systems, the use of rodents also poses challenges.  First, the relatively long 
life cycle of rats and mice place limitations on how quickly experiments can be accomplished 17.  
For example, in previous experiments accomplished in our laboratory, rats required a month of 
intravenous injections of carboplatin administered through the tail vein. This treatment procedure 
was not only stressful on the rats, but it also took a considerable amount of time on the part of the 
researchers to learn how to carry out the technique and to perform the injections. Additionally, 
after treatment, the experiments were typically more involved and time-consuming, requiring a 
great deal of effort to remove the brain and prepare it for analysis. Moreover, genetic manipulation 
of rodents, especially rats, is costly and time-consuming 18.  With this in mind, we sought an 
alternative model organism that simulates the complexity of the human central nervous system, 
but offers higher throughput and easier genetic manipulation.   
Zebrafish (Danio rerio) is a teleost that has emerged as a popular and versatile animal 
model in many research areas, such as neuroscience, toxicology, and developmental biology 19. 
One major reason for its popularity is that zebrafish is a vertebrate that has a high degree of genetic 
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and functional homology to human when compared to invertebrate models, such as fruit flies 20.   
Additionally, the use of zebrafish mitigates several disadvantages encountered with current rodent 
models. For example, zebrafish generate a large number of offspring, generally 100 to 200 
embryos, which are transparent and develop externally. 21 Additionally, zebrafish are easier to 
genetically manipulate and easier to take care than rodents.  Also, it is easy to treat the zebrafish 
with drugs or small molecules, which can be simply done by adding to the water environment or 
to the food source. These factors make zebrafish an exceptional animal model for neurotoxicity 
studies.  
Recently, our group has successfully measured dopamine release and uptake ex vivo in 
zebrafish whole brains with fast-scan cyclic voltammetry at carbon-fiber microelectrodes. In this 
work, we treated zebrafish with carboplatin and 5-fluorouracil (5-FU), two commonly used 
chemotherapeutic agents. We found that electrically-evoked dopamine release, measured with 
fast-scan cyclic voltammetry at carbon-fiber microelectrodes, was diminished in carboplatin-
treated fish, but not 5-FU-treated fish. Moreover, the route of administration appears to be 
important given that dopamine release decreased more noticeably in fish treated by oral 
administration compared to water administration.  
 
3.2 Materials and Methods.  
3.2.1 Drugs 
Pharmaceutical grade carboplatin, 10 mg/mL (CD11650AA, Hospira, Lake Forest, IL, USA), 
2.5g/50mL 5-Fluorouracil (LOT 6110679, Fresenius KABI, Bad Homburg, Germany), and 0.9 % 
sterile saline (Nova-Tech Inc, Grand Island, NE, USA) solutions were used. Dopamine was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Aqueous solutions were prepared with 
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purified (18.2 MΩ) water. A modified artificial cerebrospinal fluid (aCSF) for zebrafish whole 
brain preparations consisted of 131 mM NaCl, 2mM KCl, 1.25 mM KH2PO4, 20 mM NaHCO3, 
2mM MgSO4, 10 mM glucose, 2.5 mM CaCl2·H2O, and 10mM HEPES, and the pH was adjusted 
to 7.4. Dopamine stock solutions were prepared in 0.2 M perchloric acid and were diluted with 
aCSF without glucose to 1 µM for pre/post calibrations.   
 
3.2.2 Zebrafish   
All animal procedures were approved by the University of Kansas institutional Animal 
Care and Use Committee. Zebrafish were housed 20 fish per 2L tank in the University of Kansas 
Molecular Probes Core (KU-MPC). These animals were originally purchased from Carolina 
(Burlington, NC, USA) and kept at KU-MPC prior to the experiment. Zebrafish were maintained 
on a light dark cycle, controlled by a timer with a 16 hour light phase and 8 hour dark phase. The 
temperature of the recirculating water system was maintained at 26 ̊C. The concentration of nitrates 
were held at less than 2 ppm and pH of 7-8 was maintained. 
 
3.2.2.1 System Water Treatment with Chemotherapeutic Drugs  
To treat the system water with chemotherapeutic drugs, carboplatin or of 5-fluorouracil 
was added to a single 1L fish tank, making the final concentration 100 µM in chemotherapeutic 
agent. For this study, there were three treatment groups. Each group (n=5 fish) was treated with 
either chemotherapeutic drugs or saline (control group) for either 1 day, 4 days, or 7 days.  
Zebrafish were removed by a net from the main housing system to the tank containing drug treated 
system water. Every 48 hours, treated system water was replaced with freshly treated system water, 




3.2.2.2. Food Treatment with chemotherapeutic Drugs  
For the food delivery method of chemotherapy agents, brine shrimp (San Francisco Bay 
Brand INC, Newark, CA, USA) was thawed and the excess liquid was removed. A gram of brine 
shrimp was weighed out and soaked for 30 minutes with either carboplatin, 5-fluorouracil, or saline 
(n=5 per treatment duration) to give the shrimp an approximate concentration of 20 mg/g shrimp. 
After 30 minutes, the treated brine shrimp was added to a 1 L tank using tweezers and the fish was 
allowed to eat the treated food for 3 minutes once a day.  After the feeding period, the excess 
shrimp were removed from the system water. Prior to the electrochemical experiment, the 
zebrafish were fed with treated food for 1 day, 4 day, and 7 days.  
 
3.2.3 Electrochemistry  
3.2.3.1 Zebrafish  
All animal procedures were approved by the University of Kansas Institutional Animal 
Care and Use Committee.   Adult zebrafish used for these studies were housed in the Molecular 
Probes Core of the Center for Molecular Analysis of Disease Pathways at the University of Kansas.  
Zebrafish were euthanized by rapid chilling, also known as hypothermic shock.  To perform 
euthanasia, a separate beaker of water, taken from the Aquatic Habitats™ ZF0601 (Pentair, Cary, 
NC, USA) main housing system, was chilled to 2-4 ̊C. Zebrafish then were transferred using a net 




3.2.3.2 Zebrafish Whole Brain Preparation 
The whole brain preparation method was similar to that employed in Chapter 2. Briefly, 
Zebrafish was euthanized by the rapid chilling procedure which placing zebrafish in pre-chilled 
(2-4 ̊C) system water. Once zebrafish heads were decapitated, the heads were placed into pre-
prepared dissection pads, made with 2% agarose (BioReagent graded agarose, Sigma-Aldrich, St. 
Louis, MO, USA) in petri dishes.  The petri dish was then filled with oxygenated (95% O2 / 5% 
CO2) zebrafish ice-cold artificial cerebral spinal fluid (ZF aCSF).  The ZF aCSF consisted of 131 
mM NaCl, 2 mM KCl, 1.25 mM KH2PO4, 20 mM NaHCO3, 2 mM MgSO4, 10 mM glucose, 2.5 
mM CaCl2·H2O, and 10 mM HEPES, and the pH was adjusted to 7.4.   
The decapitated zebrafish head was then fixed by pinning it with a syringe needle.  Using 
micro tweezer, forceps, and a pulled capillary, the whole brain was carefully removed from the 
skull of the zebrafish. The harvested brain was then transferred into the recording chamber that 
was continuously perfused with oxygenated ZF aCSF, and the brain was kept at constant 
temperature of 28 ̊C.  The brain was placed ventral side face up to expose the sub pallium in 
telencephalon, then the brain was immobilized by placement of a nylon mesh harp on the top. Prior 
to the experiments, the brains were equilibrated for 1 hour. 
 
 
3.2.3.3 Carbon Fiber Microelectrodes Fabrication. 
Cylindrical carbon fiber microelectrodes were fabricated as previously described22. 
Briefly, a 7 µm diameter carbon fiber (Goodfellow Cambridge LTD, Huntingdon, UK) was 
aspirated into glass capillary tubes (1.2 mm D.D and 0.68 mm I.D, 4 in long; A-M System Inc, 
Carlsborg, WA, USA).  Loaded capillaries were then pulled using a PE-22 heated coil puller 
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(Narishige Int. USA, East Meadow, NY, USA).  Pulled carbon fibers were trimmed to a length of 
50 to 70 µm from the pulled glass tip. To seal the carbon fiber, electrodes were dipped into epoxy 
resin (EPON resin 815C and EPIKURE 3234 curing agent, miller-Stephenson, Danbury, CT, 
USA) and cured at 100 ̊C for 1 hour.  Prior to the experiments, the electrodes were soaked in 
isopropanol for 10 minutes, and the electrode surface was electrochemically pretreated by scanning 
the electrodes with the waveform of – 0.4 V to + 1.3 V back to – 0.4 V at a frequency of 60 Hz for 
15 min followed by 10 Hz for 10 min.  Electrodes were then backfilled with 0.5 M potassium 
acetate for electrical connection between working electrode and an electrode holder. 
 
3.2.3.4 Dopamine Measurements in Zebrafish Whole Brain  
Carbon-fiber microelectrodes were pre-calibrated against 1 µM dopamine, and the 
electrode surface was chemically and electrochemically purified as discussed under the electrode 
fabrication method.  The pre-calibrated carbon-fiber microelectrode and the stimulating electrodes 
(A-M System Inc, Carlsberg, WA, USA) were micromanipulated into the place by referencing the 
external features of the ventral side of the brain.  The carbon-fiber microelectrode was positioned 
50 – 100 µm laterally from the medial olfactory tract (MOT) and inserted about 280 – 300 µm 
deep.   Stimulating electrodes were placed at the center of ventral telencephalon and inserted about 
100 µm into the brain so that the carbon-fiber microelectrode was positioned between stimulating 
electrodes. 
To evoke dopamine release, 35 electrical pulses (350 µA stimulating current, 4 ms of total 
duration, and stimulating frequency of 60 Hz) were applied.  After the stimulating current was 
applied, evoked dopamine release was measured at the surface of carbon-fiber microelectrodes.  
For dopamine detection, a triangular waveform of – 0.4 V to + 1.3 V to – 0.4 V at a scan rate of 
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400 V/s was applied to the carbon-fiber microelectrode every 100 ms.  After stimulation and 
dopamine detection, the brain underwent 10 minutes of resting time before the next stimulation 
was applied. Evoked dopamine released was measured from either treated fish brain or control fish 
brain for 1 hour after the equilibration.  
 
3.2.3.5 Optimization of Stimulation Parameters 
To optimize stimulation parameters, stimulation pulses, width, and frequency were varied. 
During optimization, the waveform of – 0.4 V to + 1.3 V to – 0.4 V at 400 m/s was applied to the 
carbon-fiber microelectrodes.  The oxidation current response due to dopamine release was 
converted to concentration by a calibration factor and compared as the stimulation pulses were 
varied 1, 5, 15, 25, and 35 pulses. The stimulation width and frequency were held constant at 4 ms 
at 60 Hz. To study how stimulus duration affects dopamine release, durations of 1, 2, 3, and 4 ms 
were applied while the number of stimulation pulses and frequency were held constant at 25 pulses 
and 60 Hz. Last, to observe how the stimulation frequency influenced dopamine release, frequency 
was changed from 10, 20, 30, 40, 50, and 60 Hz while the stimulation pulse and the width were 
held at 25 pulses and 2 ms.  
 
3.2.4 Data Acquisition and Statistics 
Electrochemical measurements were collected and analyzed using an electrochemical 
workstation consisting of a Dagan Chem-Clamp potentiostat (Dagan, Minneapolis, MN, USA), 
modified to allow gain settings down to 200 nA/V, a personal computer with TarHeel CV software 
(provided by R.M. Wightman, University of North Carolina, Chapel Hill, NC, USA), a UEI 
breakout box (UNC Chemistry Department Electronics Design Facility, Chapel Hills, NC, USA), 
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and two National Instruments computer interface cards, PCI 6052 and PCI 6711 (National 
Instruments, Austin, TX, USA). 
All numerical values were represented as mean ± standard error of the mean (SEM). For 
all analyses, n is equal to the number of zebrafish brains used. GraphPad Prism 6 (GraphPad 
Software Inc, La Jolla, CA, USA) was used to conduct statistical calculations and to present data. 
 
3.2.5 Data Modeling 
Modeling was achieved by analyzing the raw data to determine the point of maximum 
dopamine signal after the application of electrical stimulation and the point where that signal has 
decayed by 80%.  This decay curve was then fit with the 1st order exponential decay equation At 
= Amax e
-kt.  Amax was held constant at the experimentally determined value and k, the 1
st order 
rate constant, was allowed to float.  The accuracy of the fit was determined by using a Pearson 
coefficient with a cut off of R > 0.8. Once this k was determined, the half-life of the decay was 
then calculated using the equation t1/2 = 0.6932/k. 
23, 24 All data analysis and curve fitting were 
performed using GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA, USA) 
 
3.3 Results and Discussion 
Recently, our lab has developed a method to detect electrically evoked dopamine release 
in the harvested whole brain of zebrafish. To extend the use of zebrafish as an animal model in 
neuroscience research, it is important to study dopamine regulation in different neurological 
systems or neurotoxicity conditions. Our group has studied post-chemotherapy cognitive 
impairment (Chemobrain) in rat animal models and has found that dopamine release and uptake 
was impaired in chemotherapy treated rats 14. Therefore, we have investigated dopamine release 
72 
 
and uptake in zebrafish treated with the chemotherapy drugs carboplatin and 5-FU. In addition, we 
administrated chemotherapy drugs to zebrafish by either treating the habitat water or by feeding 
the fish with treated brine shrimp. It was determined that dopamine release was impaired in 
carboplatin zebrafish that were treated by both habitat water and the food. However, dopamine 
release was only diminished in the 5-FU treated zebrafish treated by food administration method.  
 
3.3.1 Optimization of Stimulating Parameters 
Dopamine in the zebrafish brain can be reproducibly released by electrical stimulation to 
initiate action potential of neurons. Electrical stimulation has been a valuable method to cause the 
release neurotransmitters including dopamine both in vivo and vitro. Electrically evoked dopamine 
release in zebrafish brains needs to be sufficient enough to differentiate the changes. A stimulation 
parameter study in zebrafish has not been accomplished to the best of our knowledge. Therefore, 
we compared the amount of dopamine release as the stimulation parameters, pulse number, pulse 
width, and frequencies, were varied. First, evoked dopamine release was compared as the 
stimulating pulses were varied 1, 5, 15, 25, and 35 pulses while stimulation pulse width, current, 





Figure 1. Effect of stimulation parameters on evoked dopamine release. The concentration of 
dopamine released was compared as the number of pulses were varied from 1, 5, 15, 25, and 35 
pulses (A, top), the pulse width changes from 1, 2, 3, and 4 ms (B, top), and the stimulation 
frequency varied from 10, 20, 30, 40, 50, and 60 Hz (C, top).  Current versus time traces was also 
compared as the number of pulses (A, bottom), pulse width (B, bottom), and frequency (C, bottom) 
varied.  
 
As the number of stimulation pulses was increased, more dopamine was released into the 
extracellular space. As shown in Fig. 1A, the amount of evoked dopamine release increased 
linearly (n=5, R2 = 0.9749) as the number of stimulation pulses was increased. When 35 pulses 
were applied to release dopamine, shown in current versus time trace, the duration of signaling 
after the peak current was reached was longer compared to when lower pulses were applied. This 
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suggests that the dopamine transporters in zebrafish were not able to clear all the released 
dopamine fast enough.   
Evoked dopamine release was measured at selected pulse widths, varied from 1, 2, 3, 4 ms, 
while the number of pulses and stimulation frequency and current were held constant at 25 pulses, 
60 Hz, and 350 µA. As the pulse width gets longer, the amount of dopamine released per pulse 
increased (n=6, R2 = 0.9893). As expected, in Fig.1B, when the stimulation pulse was applied for 
4 ms, more dopamine was released compared to when the stimulation pulse was applied for 1 ms. 
Similar to other stimulation parameters, at higher stimulation frequency, more dopamine was 
electrically evoked since the number of stimulations per second increased (n=4, R2 = 0.9283). 
Therefore, for this study, we evoked dopamine release in zebrafish using 35 stimulation pulses (4 
ms per pulse) at 60 Hz.  
 
3.3.2 Evoked Dopamine Release in Chemotherapy Treated Zebrafish 
3.3.2.1 Habitat Water Treatment Method  
Electrically stimulated dopamine release in the harvested whole brain was measured using 
FSCV at carbon fiber microelectrode. Dopamine release was measured for one hour at the ventral 
telencephalon and the peak current responses were averaged and converted to the concentration 
using the calibration factor. One of many advantages of using zebrafish as an animal model is easy 
assessment of drug treatment without a complicated procedures25, such as IV tail vein injection, 
that are required in such studies using rodents animal models. 
  In this study, the habitat water is treated with either saline, carboplatin, or 5-FU. The final 
concentration of carboplatin and 5-FU in the habitat water was 100 µM. Representative data for 
control, carboplatin treated groups, and 5-FU treated groups are shown in Fig. 2. The color plot 
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and concentration versus time trace in Fig.2 suggest that there is an electroactive specie released 
due to the electrical stimulation.   
  
 
Figure 2. Representative data of evoked dopamine release in chemotherapy treated zebrafish by 
habitat water treatment. (A) Representative data of dopamine release in water treated control 
zebrafish. The oxidation current response (top) of dopamine release was sampled at the horizontal 
trance of color plot (bottom). The background subtracted cyclic voltammogram (top, insert) was 
extracted from vertical white line of color plot. (B) Representative data of dopamine release in 
carboplatin treated zebrafish after 7 days of treatment. Oxidation current response of dopamine 
release, compared to that of control, is reduced after 7 days of carboplatin treatment. (C) Evoked 
dopamine release in 5-FU treated zebrafish after 7 days of treatment. There is no changes in evoked 





Background subtracted cyclic voltammograms, which were extracted at the white vertical 
dashed line of the color plot, suggest that the released specie is dopamine.  Dopamine release 
measured in the carboplatin treated zebrafish after 7 days of treatment decreased as shown in Fig. 
2B. However, the amount of dopamine release in the 5-FU treated group did not change when 
compared to the control group.  
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Figure 3. Evoked dopamine release measured in chemotherapy treated zebrafish for different 
treatment periods.  The amount of dopamine release in carboplatin treated fish was significantly 
reduced after 7 day of treatment (n=5, two-way ANOVA p <0.05).  
 
  
               It has been suggested that diminished dopamine release might play a role in chemobrain. 
Kaplan et al.  measured dopamine release in the striatum of carboplatin treated rats and concluded 
that dopamine release and uptake were attenuated after four weeks of chemotherapy treatment14. 
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To understand if zebrafish will show a similar outcome as the rat model of chemobrain, we treated 
zebrafish not only with carboplatin but also with 5-FU, a widely used anticancer drug for various 
cancers such as breast cancer and head and neck cancer 26 . 
 Zebrafish were housed in carboplatin treated habitat water for different periods. The 
amount of dopamine release after 1, 4, and 7 days of treatment were measured and compared as 
shown in Fig. 3. At day 7, measured dopamine release was found to be 0.27 ± 0.04 µM, which is 
significantly reduced compared to the control group (n=5, two-way ANOVA, p < 0.05). Even 
though more work needs to be done, the result could suggest that carboplatin might affect zebrafish 
dopamine regulation similar to that of chemobrain rat models.  
 To examine the possible impact of other chemotherapy drugs on dopamine regulation in 
zebrafish, another group of zebrafish was treated with 5-FU. , a thymidylate synthase inhibitor and 
a known demyelinator26-28. Treatment with 5-FU was selected as the second chemotherapeutic in 
these studies because it was hypothesized that it would degrade the neuron’s ability to transmit 
signals by removing the myelin sheath, leading to diminished dopamine release27-29. Like the 
carboplatin treated group, zebrafish were housed in 5-FU treated habitat water for 1, 4, and 7 days. 
The result of dopamine release in different treatment duration groups is shown in Fig.3. Unlike 
carboplatin, dopamine release in 5-FU treated fish was not significantly changed throughout the 
treatment duration but rather increased. The number of zebrafish used for this study may need to 
increase to understand if 5-FU have no effect on dopamine release upon the habitat water 
treatment.  
 For the control group, the zebrafish were housed in saline treated habitat water for 1, 4, and 
7 days, and dopamine release was measured at each treatment duration and compared to the 
chemotherapy treated groups.  The amount of dopamine release throughout the different periods 
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was not significantly changed: Day 1 (n=5), 0.60 ± 0.14 µM; Day 4 (n=5), 0.41 ± 0.17 µM; Day 7 
(n=5), 0.63 ±0.06 µM (two way ANOVA, day 1 versus day 4, p = 0.34; day 1 versus day 7, p = 
0.99) 
 To summarize, it was found that treating zebrafish with carboplatin, added to their system 
water, resulted in a significant decrease in the maximum dopamine release observed.  This matches 
the results our lab has reported in rats14. One possible explanation for this phenomena is general 
neuronal death caused by carboplatin, a known DNA crosslinker,30, 31  is limiting the amount of 
dopamine neurons available for release, thus decreasing the observed dopamine overflow, though 
to solidify a mechanism more studies need to be done.     
Zebrafish treated with 5-FU showed no significant change in dopamine overflow was a 
surprising result.  Moreover, 5-FU is a known demyelinator which would be expected to lower the 
efficiency of action potential transfer down a neuron thus leading to less neuronal firing and less 
dopamine release.32  The fact that this was not observed is interesting and needs to be explored in 
the future. 
 
3.3.3 Food Treatment  
For the study previously discussed, chemotherapy drugs were administered by treating 
the habitat water. During this treatment the drug is most likely adsorbed through skin or the gills. 
In order to determine if treatment pathway is important in diminishing dopamine release, a 
second treatment pathway was explored. It has been reported that platinum based 
chemotherapeutic drug, such as carboplatin, can be absorbed through the small intestine of rats33; 
therefore, we introduced chemotherapy drug through their food.  
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Recently, Sterling et al. established zebrafish as model for voluntary consumption 
ethanol. They mixed ethanol with gelatin and allowed the zebrafish to freely feed on it.  
Additionally, this study examined whether delivering the ethanol to the zebrafish orally had the 
same effect on orexigenic peptides as exposing the zebrafish to ethanol treated water.34 In our 
study, brine shrimp were treated with either saline, carboplatin, or 5-FU such that the 
approximate amount of drug in the brine shrimp was 20 mg drug/g brine shrimp. Treated brine 
shrimp were then fed to each treatment group once every day for 3 min, then any remaining food 
was removed. The each group was treated for either 1, 4, or 7 days.  
Representative data of dopamine release in zebrafish that is fed with treated either 
chemotherapy drugs or saline brine shrimp for 7 days are shown in Fig. 4.  Electrically evoked 
dopamine release in zebrafish fed with carboplatin treated food, similar to water treatment method 
group, was diminished after 7 days of treatment. Interestingly, the amount of dopamine release in 
5-FU treatment group after 7 days was also reduced, this result is different from the water treated 
5-FU group and indicates that delivering the drug to zebrafish orally is the more efficient way to 





Figure 4. Representative data of evoked dopamine release in chemotherapy treated zebrafish by 
food treatment. (A) Representative data of dopamine release in control. The oxidation current 
response (top) of dopamine release was sampled at the horizontal trace of color plot (bottom). The 
background subtracted cyclic voltammogram (top, insert) was extracted from vertical white line 
of color plot. (B) Representative data of dopamine release in carboplatin treated zebrafish after 7 
days of food treatment. Oxidation current response of dopamine release was reduced after the 
treatment. (C) Evoked dopamine release in 5-fluorouracil treated zebrafish after 7 days of food 
treatment. There is no changes in evoked dopamine release after zebrafish was treated with 5-








Dopamine release in zebrafish, fed with brine shrimp treated with either saline, carboplatin, 
or 5-FU, was measured and compared in Fig. 5. For the control treatment group, like the water 
control treatment group, the different treatment duration did not affect the amount of dopamine 
released (n=5, two way ANOVA, p = 0.76).   
Carboplatin fed zebrafish shown significant impairment in dopamine released after one day 
of treatment (n=5, two way ANOVA, p < 0.05). Moreover, after 7 days of treatment, evoked 
dopamine release was further diminished (n=5, two way ANOVA, p < 0.01: day 1, 0.21 ± 0.05 
µM; day 4, 0.23 ± 0.04 µM; day 7, 0.15 ± 0.04 µM).  To elucidate the impact of chemotherapy 
intake method on dopamine release compared to water treatment method, zebrafish were fed 5-
fluorouracil treated brine shrimp.  As shown in Fig.5, the amount of dopamine release was 
diminished with 5-FU intake method not only after 7 days of treatment but also only after 1 day 
of treatment (n=5 for day 1 and day 4, n = 4 for day 7 treatment group, two way ANOVA, p < 







Figure 5. Evoked dopamine release in zebrafish measured after different periods of treatment with 
brine shrimp.  The amount of dopamine release in both carboplatin and 5-flurouracil treated fish 
was significantly reduced after 1 day of treatment (n=5, two way ANOVA, * represents p <0.05, 
** represent P <0.01).  
 
These phenomenon suggests that the effect of carboplatin on dopamine release in zebrafish 
is similar to that of results in rodent animal models.  However, when the chemotherapy drug was 
delivered orally, chemotherapy treatment was more efficient than when the drug was delivered by 
treating habitat water. This observed difference in release may be related to the amount of intact 
drug that reaches the animal.  It is not clear how much 5-FU and carboplatin can cross the skin and 
enter the blood stream; as such, it is likely that the water treated fish are receiving less than a 100 
µM dose. During food treatment, the fish are ingesting the drug instead of absorbing it through the 
skin or breathing through the gills.  Additionally, carboplatin can cross the small intestine of rats33, 
thus zebrafish are more likely to receive the entire intended dose that may lead to the observed 
increase in efficiency.  This hypothesis is supported by the fact that in the water treated fish the 
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significant changes were not observed until after day 7, whereas, in the shrimp treated, fish the 
effect was immediate. 
 
3.4 Modeling of the 1st Order Rate Constant for Dopamine Uptake 
 
Figure 6: Representative figure showing the representative data of electrically evoked dopamine 
release with the modeled data overlaid. 
 
 In the preceding sections, it has been shown that chemotherapeutic treatment has an 
effect on the release of electrically evoked dopamine. With this result in mind we wanted to 
determine if uptake was also affected by modelling the 1st order rate constant of uptake (k). 
Understanding uptake is important because of the influence it has on both the length of time 
dopamine is available to activate signaling pathways as well as the peak extracellular dopamine 
achieved after, both of these phenomenon may play a role in the observed differences discussed 
above.  The red line in Fig. 6 is a fit of the data using the equation At = Amax e
-kt   from the point 
maximum signal to 80% decay of the signal. Amax was held at the experimentally determined 
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maximum for release and k was allowed to float23, 24. The fit was determined to be valid if the 
modeled data had a Pearson coefficient greater than 0.8 when it was overlaid with the raw 
experimental data. The rate constant is a measure of the efficiency of the transporters as they 
uptake the released dopamine. The k can also be used to calculate a t1/2which is the measure of 
how long it take half of the released dopamine to be up taken.  The results of the modelling are 
shown in Fig. 7. 
It was determined that there was no significant difference between any of the treatment 
groups, because of this all the control data was pooled and an average for k was determined to be 
0.2418+ 0.018 s-1 with an n of  25 fish. This value is much larger than the reported numbers for 
both rats (0.012 to 0.027 s-1)24 and fruit flies (0.062 + 0.004 s-1)23. This could indicate a fast 
reuptake in the zebrafish compared to both rats and fruit flies. The data presented here point to 
uptake not being involved in the differences observed in max dopamine released after treatment; 
however, more work needs to be done to both calculate the Michaelis-Menten kinetic parameters 







Figure 7. The averages of the 1st order rate constant and t1/2  in chemotherapy drug treated 
zebrafish. (A). The average of 1st order rate constant (top) and t 1/2 (bottom) in zebrafish housed 
in treated system water with carboplatin or 5-FU over different treatment durations. (B). The 
average of 1st order rate constant (top) and t 1/2 (bottom) in zebrafish fed with carboplatin or 5-
FU treated shrimp food over the treatment time. There was no significant difference observed in 









The electrochemical measurement of dopamine release in zebrafish was conducted using 
fast-scan cyclic voltammetry at carbon fiber microelectrodes, and stimulation parameters were 
optimized. Furthermore, in addition to quantifying dopamine release and stimulation optimization, 
we established zebrafish as a chemobrain animal model. We investigated the changes in dopamine 
release and uptake in zebrafish that were housed in chemotherapy treated habitat water for 1, 4, 
and 7 days. Additionally, to determine if different administration methods have any influence on 
the result in dopamine regulation, the chemotherapy drugs were administered to the zebrafish with 
their food.  The data here suggest that the chemotherapy drugs have an effect on dopamine release 
and uptake in zebrafish similar to that observed in the rodent animal models. Moreover, it was 
observed that the treatment method had a significant effect on dopamine release with shrimp 
treatment showing the greater change. 
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Chapter 4. Electrochemical Measurements of 4-hydroxyphenylacetic acid and Dopamine 
with Fast-scan cyclic voltammetry 
In this chapter, we describe the electrochemical properties of 4-hydroxyphenylacetic acid, 
an electroactive by-product formed during the photoactivation of p-hydroxyphenacyl-based caged 
compounds, such as p-hydroxyphenylglutamaate.  We also have optimized fast-scan cyclic 
voltammetry waveform parameters, such as holding and switching potential and scan rates, so that 
both 4HPAA and dopamine can be detected in a single voltammogram and quantified 
simultaneously.  The results presented in this chapter are from “Simultaeous Measurement and 
Quantitation of 4-hydroxyphenylacetic acid and dopamine with fast-scan cyclic voltammetry” 
published in The Analyst, 2015,140, 3039-3047. 
 
4.1 Introduction  
The small molecule, 4-hydroxyphenylacetic acid (4HPAA), is a naturally occurring, 
electroactive phenolic compound formed in humans by the metabolism of aromatic amino acids.1 
Recent interest in phenolic compounds has centered on its propensity to become nitrated; thus, 
4HPAA has been proposed to be a biomarker for certain disease conditions that result in an 
increase of nitrosative stress.2  In addition, 4HPAA is used as a nutrient substrate in 
microorganisms that metabolize it to pyruvate and succinate during the aerobic respiration.3  More 
recently, 4HPAA has gained interest as an attenuator of DNA binding by Neisserial adhesin 
regulator (NadR) protein, a gene suppressor protein found in most hypervirulent strains of 
meningococcal bacteria 4, 5.  
  In addition to its biological functions, 4HPAA is a degradation product of the 
photoreaction of phenacyl-based caged compounds.6, 7 A caged compound possesses a photoactive 
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trigger that inhibits the activity of its biological ligand; photoactivation, induced by exposure to 
light of the proper wavelength, results in the near-instantaneous release of the photocage and 
subsequent activation of the ligand. Caged compounds have frequently been employed in the study 
of brain function, both ex vivo and in vivo. 8-11 
 The phenacyl-based photoreaction (Scheme 1) involves a Favorskii rearrangement, 
resulting in the formation of the activated biological molecule and 4HPAA.  This reaction occurs, 
in some cases, within microseconds.12 The quantitation of 4HPAA, therefore, provides an 
opportunity to indirectly quantify that amount of biologically active molecule formed by this 
reaction. Neurotransmitter molecules similar in structure to 4HPAA, such as tyramine and 
octopamine, have been shown to be electroactive and are readily detectable by fast-scan cyclic 
voltammetry (FSCV) at carbon-fiber microelectrodes. FSCV is a well-established electrochemical 
method that provides sub-second temporal resolution and good chemical selectivity when used for 
the detection of biogenic amine neurotransmitters.13 Similarly, in this study, we have found that 
4HPAA is also easily detectable by FSCV.  
 We have recently focused our efforts towards the sub-second quantitation of 4HPAA with 
the goal of quantitatively measuring the impact of caged compound photoactivation on dopamine 
release in brain tissue slices and in vivo. An important step in this process is the electrochemical 
characterization and optimization of 4HPAA with FSCV. Our results suggest that 4HPAA 
undergoes an irreversible, two-electron oxidation that involves the formation of the conjugated 
species. Moreover, we have optimized the voltammetric waveform to enhance sensitivity to 
4HPAA while also detecting dopamine simultaneously within the same scan. Using the optimized 
waveform, a limit of detection of 100 nM and a linear response up to 500 µm was found, indicating 
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that FSCV could be used to detect 4HPAA in physiological fluid as well as quantify how much 













4.2 Materials and Methods.  
4.2.1 Chemicals and Solutions.  
Dopamine (DA), 4-hydroxyphenylacetic acid (4HPAA), and 4-methoxyphenylacetic acid 
(4MPAA) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Methyl-4-hydroxyphenyl 
acetate (M4HPA) was acquired from Alfa Aesar (Ward Hill, MA).  All aqueous solutions were 
made with purified (18.2 MΩ) water.  Flow cell injection experiments were carried out in artificial 
cerebrospinal fluid (aCSF) or phosphate buffer as specified.  The aCSF consisted of 126 mM NaCl, 
2.5 mM KCl, 1.2 mM NaH2PO4, 2.4 mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3, and 20 mM 
HEPES, and the pH was adjusted to 7.4.  The phosphate buffer consisted of 3.3 mM KH2PO4 and 
5.8 mM NaH2PO4·2H2O, and the pH was adjusted to 2.71, 6.71, and 10.71.  Concentrated stock 
solutions were prepared in 0.2 M perchloric acid and were diluted with appropriate buffer for each 
experiment to desired concentrations on the beginning day of each experiment. 
 
4.2.2 Carbon-fiber microelectrode fabrication 
Cylindrical carbon-fiber microelectrodes were fabricated as previously described.14 
Briefly, a 7 μm diameter carbon-fiber (Goodfellow Cambridge LTD, Huntingdon, UK) was loaded 
into a glass capillary tube (1.2 mm O.D and 0.68 mm I.D, 4 in long; A-M system Inc, Carlsborg, 
WA, USA), which was then pulled using a PE-22 heated coil puller (Narishige Int. USA, East 
Meadow, NY).  Next, the carbon fiber was trimmed to about 30 μm from the pulled glass tip, 
which was sealed with epoxy resin (EPON resin 815C, EPIKURE 3234 curing agent, Miller-
Stephenson, Danbury, CT, USA) and cured at 100°C for 1 hour. The electrodes were backfilled 
with 0.5 M potassium acetate to obtain an electrical connection between the carbon-fiber and 
electrode holder.  Prior to the experiment, all electrodes were soaked in isopropanol for 10 minutes, 
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and then electrochemically pretreated by scanning with the appropriate waveform, used for each 
experiment, at a frequency of 60 Hz for 15 min and 10 Hz for 10 min.  A Ag/AgCl wire, locally 
fabricated, was used as the reference electrode. 
 
4.2.3 Electrochemical experiments 
FSCV data were collected with a custom-modified ChemClamp potentiostat (Dagan, 
Minneapolis, MN, USA) and TarHeel CV software provided by R.M. Wightman and M.L.A.V. 
Heien (University of North Carolina, Chapel Hill, NC, USA).  Measurements were acquired using 
a two-electrode electrochemical cell.  For flow cell injection analysis, a six-port sample injector 
valve with 2 mL sample loop was mounted on a 2-position electric actuator (Valco Inc. Houston, 
TX, USA).  As the actuator was triggered by the software, it rotated the valve to inject the sample 
for five seconds into a locally-constructed flow cell where the carbon-fiber working electrode and 
reference electrode were located. Cyclic voltammograms were collected every 100 ms.  The scan 
rate and waveform potentials were varied as needed. 
Conventional scan cyclic voltammetry was carried out using a 730E biopotentiostat (CH 
Instruments, Austin, TX) with a standard three-electrode system.  A 3 mm glassy carbon electrode 
was used as the working electrode, a platinum wire was used as the counter electrode, and a 
Ag/AgCl electrode was used as the reference electrode (CH Instruments, Austin, TX).  Prior to 
collecting measurements, the glassy carbon electrode was polished with an electrode polishing kit 
(CH Instruments, Austin, TX). For cyclic voltammetry experiments, 2 mM 4HPAA was prepared 
in aCSF (pH 7.4) and then loaded into a locally constructed electrochemical cell.  The potential 
was scanned from −0.4 V to either +1.0 V or +1.3 V, and the back to −0.4 V, at a scan rate of 10 
mV s−1. The glassy carbon electrode was re-polished between experiments, and the reference 
96 
 
electrode was stored in 1 M KCl while not in use.  For data analysis, Electrochemical Analyzer 
software (CH Instruments, Austin, TX) was used. 
 
4.2.4 Statistics 
All numerical values were represented as mean ± standard error of the mean (SEM). For 
all analyses, n is equal to the number of electrodes. GraphPad Prism 6 (GraphPad Software Inc, 
La Jolla, CA, USA) was used to conduct statistical calculations and to present data. 
 
4.3. Results and discussion 
4.3.1 Fast-scan cyclic voltammetry of 4HPAA at Standard Waveform 
The chemical structure of 4HPAA features a phenol group with an acetic acid group 
attached at the para position (Scheme 2A).  For our initial detection of 4HPAA with FSCV, a 
standard triangular waveform, similar to that used to previously detect DA, 15 was applied to a 
carbon-fiber microelectrode by linearly scanning the electrode potential from −0.4 V to +1.0 V 
and back to −0.4 V at a scan rate of 400 V s−1 and an update rate of 10 CVs s−1.   The non-faradaic 
charging current was removed by subtraction of a set of averaged background scans collected from 
the same file.  A representative CV is shown in Fig. 1A. 
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Scheme 2. Proposed oxidation reactions of 4HPAA, M4HPA, and 4MPAA. (A) Oxidation of 
4HPAA to form a conjugated species and (B) the decarboxylation of 4HPAA. (C) Oxidation of 







Figure. 1 Background subtracted cyclic voltammetry of 4HPAA. (A) Unfolded cyclic 
voltammogram of 100 μM 4HPAA in aCSF, physiological pH 7.4, obtained using the waveform 
−0.4 V to +1.0 V to −0.4 V at 400 V s−1 every 100 ms. The oxidation peak of 4HPAA was detected 
around +0.9 V on the reverse scan. (B) The color plot (bottom) and oxidation current response 
(top), taken at the oxidation peak of 4HPAA, were acquired as the carbon-fiber electrode was 
exposed to 4HPAA bolus for 5 s during the flow injection analysis.  
 
The CVs obtained by FSCV were plotted in an unfolded manner, in which the switching 
potential is located at the center of the plot, in order to clarify the location of the oxidation peaks. 
The color plot and corresponding CV revealed that a large, faradaic current peak, due to the 
oxidation of 4HPAA, occurs at approximately +0.9 V as the potential was being scanned from 
+1.0 V to −0.4 V. The occurrence of this peak on the reverse scan is atypical. For example, current 
due to the oxidation of many electroactive neurotransmitters, such as DA and serotonin (5-HT), 
occur on the front, forward scan. On the other hand, the oxidation peak of hydrogen peroxide also 
occurs on the reverse scan under similar scan parameters.16 Additionally, histamine and adenosine 
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have oxidation peaks detected on the reverse scan, exhibiting similar electrochemical behavior to 
that of 4HPAA and hydrogen peroxide.17, 18  These studies suggested that this phenomenon could 
have been caused by the time required for electron transfer. It should also be noted that the 
oxidation peak of 4HPAA occurred on the reverse scan even before filtering the file. 
A broad, shallow negative current (less than 10% of the oxidation current) also occurred 
on the forward scan. The cause of this peak is unclear; however, this particular peak does not 
appear on the first CV collected, but does appear on CVs collected 2 seconds after the electrode 
was exposed to a 4HPAA bolus (data not shown). Therefore, it is possible that the peak is caused 
by the formation and adsorption of a species as a result of the initial 4HPAA oxidation.19 However, 
it is not clear if this current is faradaic or if it occurs as a result of an alteration in the electrode 
background. 
The current response at the oxidation potential of 4HPAA is shown in Fig. 1B. This current 
trace (top) has a square response to a 4HPAA bolus during the sample injection analysis. Overall, 
the features of this CV, namely, the disparity in magnitude and the absence of a faradaic reduction 
peak on the reverse scan, suggest that 4HPAA undergoes an irreversible electrochemical reaction 
under these conditions. 
 
4.3.2 Mechanisms of Oxidation of 4HPAA 
4.3.2.1 The Effect of pH on Oxidation Current of 4HPAA 
Two potential mechanisms that could be responsible for the oxidation current in Fig. 1 
include the oxidation of 4HPAA to form a conjugated species (Scheme 2A) and/or the 
decarboxylation of 4HPAA (Scheme 2B). The conjugated species is formed by a two-electron 
oxidation reaction in which the phenolic proton and one of the protons located on the β-carbon are 
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removed. On the other hand, the decarboxylation reaction occurs when one of the protons located 
on the negatively-charged carboxylic acid group is removed, forming a radical that results in the 
release of a carbon dioxide molecule. 
To examine these potential mechanisms, we obtained CVs of 4HPAA and the related 
compounds, methyl-4-hydroxyphenyl acetate (M4HPA) and 4-methoxyphenylacetic acid 
(4MPAA) (Schemes 1C and D, respectively) at pH values of 2.71, 6.71, and 10.71 (Fig. 2). The 
same electrochemical parameters employed in Fig. 1 were used for these pH studies. At all pH 
values, 4HPAA and M4HPA showed substantial faradaic oxidation currents that occurred on the 
reverse scan at about +0.9 V and +0.8 V, respectively, while 4MPAA showed no appreciable 
current at any pH. The pH value significantly impacted the oxidative current; responses 
progressively decreased for 4HPAA and M4HPA, with the highest current observed at pH 2.71 












Figure. 2 Changes in oxidation signal of 4HPAA and M4HPA in response to pH. (A) Unfolded 
CVs of 4HPAA and M4HPA at pH values of 2.71 (left), 6.71 (center), and 10.71 (right). Oxidation 
peaks of both species were detected on the reverse scan. (B) The effect of pH on oxidation current 
of 4HPAA and M4HPA. Both species showed similar overall current trends in response to changes 
in pH. There was a significant pH-driven effect on oxidation current (p = 0.0007, n = 4, two-way 
ANOVA, F(2,90) = 56.94).  
 
 
The evidence presented here suggests that the oxidation of 4HPAA proceeds through the 
formation of conjugated species.  The para-methoxy derivative form of 4HPAA, 4MPAA, showed 
only a negligible oxidation current compared to 4HPAA.  This is not surprising, given that the 
methoxy group on the ring would be expected to make the formation of the conjugated species 
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energetically unfavorable. On the other hand, M4HPA showed an oxidation current similar to 
4HPAA at all pH values.  Given that both M4HPA and 4HPAA possess an oxidizable phenol 
group, both compounds can readily form the conjugated species (Schemes 2A and C). 
 The idea that M4HPA and 4HPAA undergo similar oxidation mechanisms is supported by 
other reports in which the redox behavior of parabens and other analogues was investigated.21  Gil 
et al. have employed an electrochemical method to investigate the association between the 
inductive effect of different types of parabens and their redox behavior.20  This study suggests that 
the phenolic hydroxyl group affects the oxidation state of parabens; thus, changes in pH influence 
redox reactions, especially those involving H+. 
This overall trend of decreasing oxidation current with decreasing pH seems to be 
influenced by pH-induced charged states of 4HPAA and M4HPA.  The pKa values of the phenolic 
carboxylic acid and hydroxyl group of 4HPAA are 4.48 and 9.67, respectively; thus, 4HPAA is 
neutral under highly acidic conditions and negatively charged under neutral and basic conditions.21  
However, the pKa value of M4HPA is 8.4, making M4HPA neutral under both acidic and neutral 
conditions and negatively charged under highly basic conditions.  When the waveform in Fig. 1 is 
employed, the surface of the carbon-fiber microelectrode is held at a potential of −0.4 V during 
the 93 ms that elapses in between 7 ms-duration voltage sweeps.  This electron-rich state would 
be expected to promote adsorption of positively-charged species while repelling negatively-
charged species.  Our observations in Fig. 2 are consistent with this logic.  The oxidation currents 
for both 4HPAA and M4HPA are lowest at a pH of 10.71, conditions under which both species 
are negatively charged, and are greatest at a pH of 2.71, at which both species are neutral in charge. 
The currents arising from the oxidation of M4HPA are greater than those arising from 
4HPAA oxidation at pH values of 6.71 and 10.71.  This difference likely occurs because 4HPAA 
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possesses a single negative charge compared to the neutral charge state of M4HPA at a pH of 6.71. 
Similarly, 4HPAA has a double negative charge while M4HPA has a single negative charge at a 
pH of 10.71.  The increased negative character of 4HPAA would be expected to decrease its 
association with the negatively-charged electrode surface to a greater extent than M4HPA, thereby 
decreasing the measured oxidation currents of 4HPAA at neutral and basic pH. 
In addition to altering the charge state of the molecules of interest, pH can also influence 
the carbon-fiber microelectrode surface.  Oxide groups on the surface can undergo protonation and 
deprotonation as environmental pH changes, thereby affecting electrochemical responses.19 22, 23 
Moreover, the changes in pH tend to influence redox reactions, especially those involving a loss 
or gain of H+, as is commonly observed in phenolic compounds.24 It is not clear if these 
modifications would differentially influence oxidation currents obtained from 4HPAA and 
M4HPA. 
 
4.3.2.2 The Effect of Scan Rates on Oxidation Current at the Standard Waveform. 
Currents measured at the electrode may be controlled in two fundamental ways: (1) the 
electron transfer reaction of 4HPAA adsorbed onto the electrode surface cannot keep up with the 
high scan rates employed when using FSCV (electron transfer-limited current) and (2) the 
oxidation currents are limited by the ability of 4HPAA to diffuse to the electrode due to the high 
scan rates employed (diffusion-limited current).  To determine if the current is adsorption- or 
diffusion-limited, we obtained CVs at scan rates ranging from 100 to 800 V s−1 (Fig. 3). When the 
current response was plotted against various scan rates, shown in Fig. 3A, linear responses were 
observed up to 500 V s−1 (R2 = 0.9882), suggesting that the electrochemical reaction is adsorption 
dependent up to this scan rate.25 At scan rates greater than 500 V s−1, linearity is lost; however, 
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when these current responses were plotted versus square root of scan rate, as shown in Fig. 3B, the 
plot yielded a linear trace (R2 = 0.9822), suggesting diffusion control.15, 26 Therefore, we conclude 
that electron transfer kinetics for 4HPAA oxidation are influenced mostly by adsorption at scan 
rates below 500 V s−1, and diffusion at scan rates greater than 500 V s−1.17 These factors likely 
contribute to the movement of the peak from higher to lower potentials (Fig. 3C), that is, the 




Figure. 3 The effect of scan rate on currents generated from the oxidation of 4HPAA. (A) Plot of 
current versus scan rate. The R2 value applies to measurements obtained from 100 to 500 V s−1. 
(B) Plot of current versus the square root of the scan rate. CVs were obtained using the waveform 
−0.4 V to +1.0 V to −0.4 V at selected scan rates. The currents were obtained from the oxidation 
peaks. (C) Plot of oxidation potential (Eox) versus scan rate. 
  
4.3.2.3 Fast-Scan Cyclic Voltammetry of 4HPAA at Extended Waveform 
To determine if additional oxidation processes can be induced at higher potentials, the 
waveform was modified so that the potential was scanned up to +1.3 V, while the holding potential 
was still maintained at −0.4 V at 400 V s−1 (Fig. 4).  The resulting CV revealed the formation of 
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two individual oxidation peaks, indicating the occurrence of two distinct electrochemical processes 
(Fig. 4A). The first and second peaks were observed at +1.2 V on the forward scan (‘peak 1’) and 
at +1.0 V on the reverse scan (‘peak 2’), respectively.  To understand the possible mechanism of 
these two oxidation peaks’ formation, the current traces were analyzed.  The current for peak 1 
increased more rapidly upon 4HPAA injection compared to peak 2 (Fig. 4B, top) and reached a 
steady state almost before the second oxidation peak had begun to form.  These traces are 
consistent with a mechanism in which the primary oxidation reaction, resulting in peak 1, is 





Figure. 4 Fast-scan cyclic voltammetry of 4HPAA. (A) Unfolded cyclic voltammogram of 100 
μM 4HPAA in aCSF (pH 7.4) obtained using the waveform −0.4 V to +1.3 V to −0.4 V at 400 V 
s−1 repeated every 100 ms. Two oxidation peaks were observed, one around +1.2 V on the forward 
scan and the other one around +1.0 V on the reverse scan. (B) Color plot (bottom) and current 




4.3.2.4. Conventional Cyclic Voltammetry of 4HPAA  
Further analysis of 4HPAA with conventional cyclic voltammetry was conducted for 
comparison.  For this experiment, a three electrode system was used.  The potential at a glassy 
carbon electrode, immersed in a solution of 2 mM 4HPAA in aCSF, was scanned from −0.4 V up 
to +1.0 V and back to −0.4 V at a scan rate of 10 mV s−1 (Fig. 5A).   In contrast to the measurements 
obtained with FSCV, the oxidation peak was detected at +0.65 V on the forward scan.   Moreover, 
when the electrode was scanned up to the higher switching potential of +1.3 V, the two oxidation 




igure. 5 Conventional cyclic voltammetry of 4HPAA prepared in aCSF (pH 7.4). (A) CV obtained 
using the waveform −0.4 V to +1.0 V to −0.4 V showing a single faradaic peak. (B) CV obtained 
using the waveform −0.4 V to +1.3 V to −0.4 V showing the appearance of an additional peak at 
+1.06 V. The dashed line denotes the location of the +1.0 V potential. The concentration of 




Although the electrochemical mechanism underlying the formation of this second peak is 
not clear, it is possible that a dimerization occurs. The phenol group of the 4HPAA molecule is 
reactive since the proton from the hydroxyl group is acidic. Therefore, as the oxidation potential 
is applied to the electrode, the first electron is transferred from the phenol to the electrode, forming 
a phenoxy radical that further couples with another 4HPAA molecule to electrochemically 
generate a dimer, similar to that occurring with other phenolic compounds.20, 21, 27-29 As the dimer 
forms, the second electron transfer takes place, which would be responsible for the second 
oxidation peak.21 
During the collection of multiple CVs, the oxidation current of 4HPAA dropped 
substantially after the first scan, necessitating that the electrode must be polished between each 
scan (data not shown). With this in mind, it should be mentioned that poly-4HPAA can passivate 
the electrode surface, resulting in electrode fouling and slower electron transfer. Nevertheless, 
electrode fouling appeared not to substantially impact current from the FSCV experiments. One 
explanation for this is that the electrode was scanned at such a high rate that there is not enough 
time for electrodeposition to occur.21 
 
4.3.3 Optimization of FSCV scanning parameters 
To minimize the effect of the secondary product (peak 2) while enhancing the response of 
the main peak (peak 1), oxidation current responses of 4HPAA at different switching potentials, 
holding potentials, and scan rates were studied.  First, we obtained CVs containing both main and 
secondary peaks at selected switching potentials ranging from +1.0 V to +1.4 V at the constant 
holding potential of −0.4 V and a scan rate of 400 V s−1.  Overall, the current response of peak 1 
increased as the switching potential was changed from +1.0 V to +1.4 V (Fig. 6A).   A slight drop 
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in current was found at +1.4 V. As higher switching potentials are applied, the hydrophobicity of 
the carbon-fiber electrode surface changes by increasing the number of oxide groups, which 
improves the electron transfer kinetics at the electrode surface and enhances sensitivity.30, 31     Such 
an improvement could also arise from an increase in the microscopic area of the electrode surface 










Figure 6. Optimization of FSCV scanning parameters. (A) Effect of switching potential on 
oxidation current for the primary peak (circles) and secondary peak (squares) was studied. 
Switching potential was varied between +1.0 V and +1.4 V while holding potential was held 
constant at −0.4 V using a scan rate of 400 V s−1. (B) The holding potential was varied from −0.5 
V to +0.2 V while the switching potential was held at +1.0 V with a scan rate of 400 V s−1. Current 
responses of peak 1 (circle) and peak 2 (square) at each holding potential were plotted. (C) 
Dependence of oxidation current of peaks 1 and 2 on scan rate (C) and square root of scan rate 
(D). The waveform −0.4 V to +1.3 V to −0.4 V was used (for all figures p < 0.001, n = 4, peak one 
compared to peak two, two-way ANOVA).  
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The current response due to the secondary reaction also increased with greater switching 
potential in the fast-scan CV traces, but not as much as the main peak. In fact, the current response 
of peak 1 was more than double that of peak two at +1.3 V.  A similar effect has been well-
documented when measuring DA.36, 37 Therefore, in order to optimize the ability of FSCV to 
measure DA, while also enhancing the 4HPAA signal, we selected +1.3 V as the switching 
potential. 
Current response was measured at selected holding potentials (between −0.5 V and +0.2 
V) while maintaining a switching potential at +1.3 V at a scan rate of 400 V s−1. (Fig. 6B).  4HPAA 
is negatively charged at the physiological pH, so we expected to see lower current responses for 
both peak 1 and peak 2 due to the repulsive action between the negatively charged electrode and 
4HPAA conjugate base.  However, a higher current response for peak 1 was observed as more 
negative holding potentials were applied except at −0.5 V, due to the unreliable background current 
at lower holding potentials.17  This enhancement of catecholamine signal at negative holding 
potentials had previously been suggested to occur as a result of the increased amount of adsorption 
at the electrode surface.15  The adsorption of 4HPAA apparently plays a major role, thereby 
explaining the current response increases that occur as the holding potential becomes more 
negative. 
Increasing scan rate has also been shown to enhance the current response of adsorbed 
species (see Fig. 3).38 Fig. 6C shows a plot of oxidation current of 4HPAA versus scan rate.  As 
expected, the current for both peak 1 and peak 2 increased with scan rate.  As faster scan rates are 
applied, the time spent at the holding potential increases, which also increases the amount of time 
for adsorption as well.  Even though the highest current is obtained at the scan rate of 800 V s−1, 
we decided to use 600 V s−1 as an optimized parameter.  This choice represents a compromise.  At 
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high scan rates, faradaic currents can be buried under the background current36 which is 
proportional to the scan rate.22 Moreover, DA, as well as other electroactive neurotransmitters, 
undergo hysteresis—the oxidation occurs at a more positive potential, the reduction occurs at a 
more negative potential—which may cause increased overlap with the 4HPAA peak.15, 39 
 
4.3.4 Cyclic voltammetry of 4HPAA and DA 
One of our goals is to be able to quantify how much 4HPAA has been photo-released from 
p-hydroxyphenacyl-based caged compounds.6, 40 A specific application of this approach is the 
photorelease of glutamate, the most abundant excitatory neurotransmitter in the central nervous 
system,41 in brain tissue and measuring subsequent alterations in the electrically evoked release of 
DA. This approach has the advantages of being able to apply glutamate within short timeframes 
and confined spatial dimensions.  Both of these advantages are critical because glutamate is 
excitotoxicity, 42 making the bath application of brain slices impractical.  
Unfortunately, determining with high precision the amount of glutamate, or any other 
caged compound that has been photoreleased, has historically relied upon experimental 
determination of the number of moles of photons per second supplied by the light source and 
multiplying this parameter by the quantum yield (moles of compound photoreleased/moles of 
photons supplied) of the caged compound of interest.8  This method is inherently imprecise due to 
variations in the output of the light source as well inconsistencies in tissue density at various 
recording sites.   
One goal in the electrochemical characterization of 4HPAA is to use this electrochemical 
signature to quantify glutamate photorelease within brain tissue slices more reliably than the 
existing method described, independent of the number of photons reaching the tissue. Therefore, 
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it is important to optimize our voltammetric parameters for the simultaneous detection of DA and 
4HPAA. 
To enhance the peak separation, voltammetric measurements were obtained from a mixture 
of 4HPAA (100 μM) and DA (1 μM) at selected switching potentials while the holding potential 
was kept at −0.4 V (Fig. 7A). As shown, the separation of peak oxidation potential (Eox) between 
4HPAA (100 μM) and DA (1 μM) was greatest at a switching potential of +1.3 V. The use of 
higher switching potentials is not well-suited for the detection of dynamic changes of 
catecholamine release due to the increased response time.37 Therefore, we decided to use +1.3 V 
in the optimized waveform. Holding potential and scan rate did not significantly affect peak 













Figure. 7 Cyclic voltammetry of 4HPAA and DA at optimized waveform. (A) Study of oxidation 
peak potential of 100 μM 4HPAA and 1 μM DA. (n = 4, p < 0.0001, two-way ANOVA). (B). 
Concentration study of 4HPAA in the presence of DA. Current responses of the primary oxidation 
peak was plotted against 4HPAA concentration. (n = 3, p = 0.0091, t-test) (C) Unfolded CV of 
4HPAA and DA. Three oxidation peaks were observed, oxidation peak of DA and 4HPAA (peak 
1) were shown on forward sweep and 4HPAA (peak 2) on reverse sweep. (D) Color plot (bottom) 





An example of the detection of 4HPAA and DA using this optimized waveform is shown 
in Fig. 7C and D. The oxidation peaks for both 4HPAA (peak 1) and DA rise rapidly after injection. 
Moreover, the peaks are clearly separated on the CV.  The optimized waveform was used to 
measure the current signal of a mixture of 4HPAA and DA at selected concentrations (Fig. 7D).  
The current traces of both peak 1 and 2 have square responses due to the sample injection 
compared to that of DA, which shows a slower response under the same conditions. A similar 
difference in current response has been shown between DA and ascorbate. This is likely due to 
DA being strongly adsorbed and desorbed at the electrode surface.15 For the data analysis on the 
calibration curve, the current was taken at the main oxidation peak of 4HPAA. Fig. 7B shows the 
oxidation current responses of the main peak as a function of 4HPAA concentration which was 
varied from 0.1 μM to 100 μM in the presence of 1 μM DA in solution. The oxidation current of 
4HPAA increases linearly with the concentration with correlation coefficient of 0.9905 up to 20 
μM and 0.9701 up to 100 μM. The limit of detection of 4HPAA was found to be 100 nM based on 
the signal to noise ratio of 3. 
 
4.4. Conclusions 
The goal of this study was to develop a method to quantitatively and simultaneously 
measure sub-second changes in DA and 4HPAA levels. Our intent is to apply this method to 
examine neurotransmitter interactions in brain slices as well as in vivo. We found that the optimum 
waveform for the detection of 4HPAA was to scan linearly from a holding potential of −0.4 V to 
+1.3 V and back to −0.4 V at a scan rate of 600 V s−1. This waveform provided good limits of 
detection and sensitivity for the measurement of 4HPAA. Moreover, this optimized waveform was 
effective for the simultaneous detection of 4HPAA and DA. Along with quantifying 4HPAA in 
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biological preparations, the results from this work will allow the electrochemical measurement of 
photoactivation reactions that generate 4HPAA as a by-product as well as provide a framework 
for measuring the photorelease of electroactive by-products from caged compounds that 
incorporate other chromophores. 
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Chapter 5. Conclusions and Future Directions.  
5.1 Electrochemical Measurements of Evoked dopamine Release in Zebrafish 
 For the first time, we were able to measure evoked dopamine release and uptake in a 
harvested zebrafish whole brain with fast-scan cyclic voltammetry at a carbon-fiber. 
microelectrode.  Conducting several pharmacological manipulations provided strong evidence 
that the electrochemical species released due to the stimulation is dopamine.  One of the unique 
benefits we discovered while using the harvested whole zebrafish brain is that the brain is small 
enough to stay viable for more than 6 hours which allows us to conduct any pharmacological 
studies needed. Moreover, using the intact whole brain allow us to preserve the entire neuronal 
circuitry and leads to the possibility of studying that circuitry, especially the dopaminergic 
neuronal pathway. Besides, the use of the whole brain could allow us to understand how the 







Figure 1. Representative data of evoked dopamine release due to remote stimulation. Image of 
the harvested whole brain with stimulation electrodes positioned at ventral diencephalon as the 
carbon-fiber microelectrode is positioned at the ventral telencephalon to measure dopamine 
release after remote stimulation (left). The concentration versus time plot (right, top) was 
sampled from the horizontal dashed white line of the color plot (right, bottom) and the cyclic 
voltammogram (right, top insert), sampled from the vertical dashed white line of the color plot, 
indicates that the electrochemical change observed in the color plot is indeed dopamine released 
due to the remote stimulation.  
 
Many histochemical and imaging studies have suggested that the zebrafish’s dopamine 
neurons send an ascending projection from the ventral diencephalon to the ventral telencephalon. 
1 To expand the use of zebrafish as a model to study these projections, we have tried to evoke 
dopamine release remotely. As shown in Fig. 1, dopamine release at the ventral telencephalon 
was observed while applying stimulation at the ventral diencephalon. Stimulation parameters of 
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350 µA, 35 pulses, 4ms per pulse, at 60 Hz were used in order to evoke dopamine release. This 
very promising preliminary data points towards our group having the ability to stimulate the 
dopamine pathway, thus allowing us to study dopamine’s circuitry in zebrafish without having to 
use in vivo methods 
Once we establish a robust protocol to measure remotely stimulated dopamine release, 
we can conduct experiments to determine if pharmacological agents show the same affect during 
both local and remote stimulation.  Moreover, we can determine how the dopaminergic pathway 
is involved in different neurotoxicity events, such as chemobrain.  
 
Figure 2. Representative data of locally stimulated dopamine release in an ex vivo whole brain 
mount. The image of the whole intact brain in a euthanized and decapitated zebrafish head is 
shown with both the working and stimulation electrodes inserted dorsally rather than ventrally 
(left). The concentration versus time plot (right, top) due to dopamine release and the cyclic 
voltammogram (right, top insert) suggest that dopamine can be released while brain is still intact 




The ultimate research goal for the zebrafish study will be the development of methods to 
measure dopamine release in vivo. We were able to measure evoked dopamine release in a 
euthanized zebrafish. After the zebrafish was euthanized, the head was decapitated and part of 
the skull was removed exposing the dorsal portion of the entire zebrafish brain. Then, as shown 
in Fig. 2, we inserted stimulation electrodes and a carbon-fiber microelectrode dorsally rather 
than ventrally. Dopamine was released after the application of 120 pulses, 100 µA, and 
frequency of 60 Hz. It is important to mention that we were able to access the ventral side of 
zebrafish brain while electrodes are introduced from the dorsal side and successfully measure 
dopamine release. The data presented in Fig. 2 is promising because it demonstrates this was 
possible, an important first step towards developing in vivo methods in zebrafish. These 
methods, once fully developed, will allow other researchers to use the zebrafish as a model for 
neurotoxicity that that can lead to potential therapeutic interventions.  
 
5.2 Dopamine release in chemotherapy treated zebrafish.  
In this study, we treated zebrafish with two different chemotherapy drugs, carboplatin 
and 5-fluorouracil, that are used to treat many cancers. We also have treated the zebrafish in two 
different pathways; habitat water treatment and food treatment. Dopamine release in zebrafish 
treated with carboplatin through both habitat water treatment and food treatment was diminished; 
the same result was shown in chemotherapy treated rats. Moreover, zebrafish were treated with 
5-fluorouracil and dopamine release was measured. The data acquired suggested that dopamine 
release in zebrafish that were fed with 5-flurouracil treated food was reduced; however, there 
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was no significant changes in dopamine release from zebrafish that were housed in treated 
habitat water.  
To determine if dopamine release impairment in chemotherapy treated zebrafish is due to 
dopamine synthesis disruption or alteration of dopamine receptors function, we will need to 
study the total content of dopamine available in zebrafish brain. To carry out this experiment, we 
are currently developing quantification method using mass spectrometry. This study will provide 
information relating to how the total content of dopamine differs in control and chemotherapy 
treated zebrafish. Furthermore, we will study dopamine release and uptake kinetics using 
modeling software written by R.M Wightman (University of North Carolina, Chapel Hills, NC, 
USA).  
 This modeling software will allow us to determine dopamine per pulse, which is the 
amount of dopamine released per stimulation, and V max, which is the maximum rate of released 
dopamine uptake. 2, 3 This is valuable information that can be used to study the kinetics of 
dopamine release and uptake. However, to model the data, the software requires a Km value that 
will be held constant, this value describes how the dopamine transporter functions. The Km 
value in rats and mice is known to be about 0.2 µM 4; however, there is no known Km value 
available for zebrafish. Therefore, our group, in the future, plans to determine the Km value in 
zebrafish by introducing known amounts of dopamine into the ventral telencephalon and 
measure how fast dopamine is uptaken. Once the Km value is determined, we can use this Km 






5.3 Measurement of 4HPAA and dopamine in cage compounds study.  
In this study, electrochemical characterization and mechanism of 4HPAA was studied 
with fast-scan cyclic voltammetry at a carbon fiber microelectrode. An optimized waveform was 
developed and found to be effective for the simultaneous detection of both 4HPAA and 
dopamine in a single measurement. The goal of these studies was to develop a method to 
quantify the amount of biologically active compound photo-released after photoactivation of p-
hydroxyphenacyl (pHP) based caged compounds, especially pHP glutamate. This study is 
innovative because glutamate cannot be quantified using electrochemical method due to it being 
non-electroactive.  
In addition to optimizing the detection of 4HPAA, our research group has been interested 
in incorporating fast-scan cyclic voltammetry detection within a microfluidic device.  Moreover, 
our group wants to study how different concentrations of glutamate influence dopamine 
regulation in the zebrafish brain using caged compounds. To conduct caged compound 
experiments in mice brain slices, we use a mercury lamp as a light source that is modulated with 
a computer controlled shutter. The light is delivered by 100 µm diameter fiber optic cable which 
is positioned by a micromanipulator. However, there are a couple of challenges during the 
electrochemical detection of 4HPAA and dopamine upon the photo-release of pHP-glutamate on 
brain slices. To perform the experiment, the stimulation electrodes, carbon fiber electrode, and 
the fiber optic cable need to be positioned in the same spot with a specific geometry over the 
brain slice. This is challenging since there is limited space to position all the electrodes between 
recording chamber and microscope objective lenses. Moreover, a large amount of pHP-
glutamate, which must be custom synthesized and is available in limited quantities, is required to 
perfuse the compound over the brain slice. To perform our experiments in a more cost effective 
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and efficient manner, our group was interested incorporating the caged compound experiment 
with microfluidic systems, which requires the use of small volume of solvent.  
Microfluidics has emerged as a powerful technology in bioengineering, bioanalytical, and 
pharmacological research over the past decade. 5-7   The miniaturization of a system offers 
several advantages, for example, fast analysis time, high throughput, and the ability to 
incorporate numerous detection techniques. 8, 9 Mass spectrometry, laser induced fluorescence, 
and optical measurements are the most common detection systems incorporated with 
microfluidics. However, these detection systems are typically employed in a “off-chip” format 
since these system are significantly large. Therefore, electrochemical detection can be ideal for 
use in a microfluidic system since different shapes and types of microelectrodes can be easily 
fabricated on chips. Constant potential amperometry has been widely used as an electrochemical 
detection method in microfluidics due to its simplicity, but suffers from poor chemical selectivity 
compared to fast-scan cyclic voltammetry. Since fast scan cyclic voltammetry in a “on-chip” 
format has not been demonstrated, we need to prove that it is feasible to use with a microfluidic 
system.  
The microfluidic chip is made of polydimethylsiloxane (PDMS), which is a silicon-based 
polymer widely used for microfluidic chip fabrication. The top layer consists of a 50 µm wide 
single flow channel with two reservoirs and the bottom layer contains a 30 µm carbon fiber 
(Specialty Materials, INC. Lowell, MA, USA) positioned perpendicular to the flow channel. To 
bond the top and bottom layers and embed carbon-fiber electrode onto the PDMS chip, we 
modified a spin coating fabrication method. Schematic diagram of the chip fabrication process 
can be found in Appendix 1.  A sequential injection using gravity feed as the main driving force 
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was applied to introduce sample to the microfluidic channel, shown in Appendix 2.  Using this 
injection method, 32 nL of sample was injected each time at the flow rate of 1.8 µL/min.  
Using this device, we were able to detect dopamine and serotonin.  In the future, to test 
the feasibility of the chip, we will measure neurotransmitters in physiological samples such as 
microdialysates and urine. These collected data suggests that fast scan cyclic voltammetry can be 
employed on microfluidic chip requiring only about 32 nL of sample. In addition, we will also 
further develop a microfluidic device that consists of a micro-vessel to deliver caged compound 
and a recording chamber to contain neural tissues to keep the tissue viable.   
 
 
Figure 3. Representative data of the dopamine and serotonin detection using on-chip fast scan 
cyclic voltammetry the flow cell microfluidic chip.  Cyclic voltammograms of 5nM dopamine 
(A) and 100 nM serotonin (B) were taken with a triangular waveform of -0.4V to +1.5V at 400 
V/s every 100 ms. The oxidation peak dopamine can be observed at around 0.6 V and reduction 
peak at around -0.4 V. In addition, serotonin exhibited two oxidation peaks and one reduction 
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Appendix 1.  Diagram of the modified spin coating chip fabrication. (A) Basic diagram 
of the spin coating method that creates a 26 µm thin film of PDMS on the glass slide 
(insert). (B) Schematic of the chip fabrication process shown step by step. 1. A pre-
prepared mixture of 10:1 ratio PDMS and curing agent was poured at the center of the 
glass slide. The PDMS was deposited on top of the glass slide using spin parameters of 
4000 rpm for 45 s with acceleration of 300 rpm/s. 2. Spin coated PDMS was pre-baked at 
70 ºC and a trimmed 30 µm carbon-fiber was placed on the partially cured PDMS. 3. 
Post-baked the chip for 10 minutes at 70 ºC to seal the carbon fiber with the PDMS. 4. 
The fully cured top layer was bonded with post-baked bottom layer and the completely 





Appendix 2. The diagram of the sequential injection method. (A). Experimental set up 
for the sequential injection method. A fused silica capillary (1cm long and 50 um in 
diameter) was inserted into a flow channel and sealed with epoxy glue. An Ag/AgCl 
reference was positioned inside of the tubing which was connected to the outlet of the 
flow cell, achieving a closed system for gravity feed. (B). Diagram of gravity sample 
injection.  Connection tubing (30 cm), flow channel, and capillary were filled with buffer 
solution using a 5 mL gastight glass syringe (top).  As the syringe is disconnected, the 
buffer is withdrawn from the capillary into the flow channel (bottom). Once the flow was 
achieved as described above, the position of the buffer droplet was switched with the 
sample droplet C. micrograph of sample injection through the microfluidic flow cell.  
 
 
 
